{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:56:04Z","timestamp":1790139364391,"version":"4.0.1"},"reference-count":391,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer immunotherapy has substantially advanced cancer treatment, achieving durable responses in select malignancies. However, its widespread application is limited by significant challenges: low efficacy in many solid tumors, severe side effects, and immune evasion facilitated by the tumor microenvironment (TME). Nanotechnology offers a promising approach to address these obstacles. By employing nanoparticles (NPs), we can precisely deliver therapeutics to tumor sites, ensure controlled release to minimize side effects, and amplify the immune response, thereby substantially boosting the effectiveness of immunotherapy. This review comprehensively highlights the latest advancements in using nanotechnology to enhance cancer immunotherapy. This paper details various applications of nanotech in this field. It discusses smart nanoparticles that respond to TME signals to release drugs (e.g., checkpoint inhibitors) directly at the tumor, reducing systemic side effects and activating T-cells. We also explore how nanovaccines, which co-deliver tumor markers and immune boosters, can induce antigen-specific immune responses. Furthermore, mRNA-loaded nanoparticles can directly modify CAR T-cells inside the body, simplifying treatment and increasing efficacy. Strategies like using PLGA NPs to deliver immune enhancers such as IL-2 are also presented, which activate immune cells while minimizing systemic issues. The review also explains how nanoparticles can re-engineer the immunosuppressive TME to create an environment more conducive to immune action. We also emphasize that nanotechnology-enhanced adoptive therapies, particularly cytokine-induced killer (CIK) cell immunotherapy, hold great potential to improve tumor targeting, treatment persistence durability, and overall anticancer efficacy. Collectively, we highlight synergistic effects achieved by combining nanoparticles with other treatments like chemotherapy, radiation, photothermal\/photodynamic therapy, and more, which can turn hard-to-treat tumors into susceptible targets. The integration of nanotechnology and immunotherapy holds the potential to meaningfully advance future cancer therapy.<\/jats:p>","DOI":"10.1186\/s12943-026-02736-0","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:56:26Z","timestamp":1785250586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies"],"prefix":"10.1186","volume":"25","author":[{"given":"Untack","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhyuk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyeon","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yona","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyung Won","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Eun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Sung","family":"Myeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ran","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo G. H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ha","family":"Paek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2736_CR1","doi-asserted-by":"publisher","unstructured":"Sung H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"2736_CR2","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela DT, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:205031212110343. https:\/\/doi.org\/10.1177\/20503121211034366.","journal-title":"SAGE Open Med"},{"key":"2736_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52:17\u201335. https:\/\/doi.org\/10.1016\/j.immuni.2019.12.011.","journal-title":"Immunity"},{"key":"2736_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the immune system and its therapeutic potential. Cell Mol Immunol. 2020;17:807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"key":"2736_CR5","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27:S87\u201397. https:\/\/doi.org\/10.3747\/co.27.5223.","journal-title":"Curr Oncol"},{"key":"2736_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"key":"2736_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"key":"2736_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360\u201378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0.","journal-title":"Nat Rev Cancer"},{"key":"2736_CR9","doi-asserted-by":"publisher","unstructured":"Bernstein ZJ & Spangler JB. Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies. J Clin Invest. 2021; 131. https:\/\/doi.org\/10.1172\/jci152857","DOI":"10.1172\/jci152857"},{"key":"2736_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"2736_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res. 2016;22:1865\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1507.","journal-title":"Clin Cancer Res"},{"key":"2736_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"2736_CR13","doi-asserted-by":"publisher","unstructured":"Kennedy LB & Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020; 70: 86\u2013104. https:\/\/doi.org\/10.3322\/caac.21596","DOI":"10.3322\/caac.21596"},{"key":"2736_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"key":"2736_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"RK Jain","year":"2005","unstructured":"Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58\u201362. https:\/\/doi.org\/10.1126\/science.1104819.","journal-title":"Science"},{"key":"2736_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19:237\u201353. https:\/\/doi.org\/10.1038\/s41571-021-00588-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"2736_CR17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","volume":"21","author":"S Upadhaya","year":"2022","unstructured":"Upadhaya S, Neftelinov ST, Hodge J, Campbell J. Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discovery. 2022;21:482\u20133. https:\/\/doi.org\/10.1038\/d41573-022-00030-4.","journal-title":"Nat Rev Drug Discovery"},{"key":"2736_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","volume":"19","author":"MS Goldberg","year":"2019","unstructured":"Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19:587\u2013602. https:\/\/doi.org\/10.1038\/s41568-019-0186-9.","journal-title":"Nat Rev Cancer"},{"key":"2736_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"JD Martin","year":"2020","unstructured":"Martin JD, Cabral H, Stylianopoulos T, Jain RK. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17:251\u201366. https:\/\/doi.org\/10.1038\/s41571-019-0308-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"2736_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","volume":"157","author":"J Fang","year":"2020","unstructured":"Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev. 2020;157:142\u201360. https:\/\/doi.org\/10.1016\/j.addr.2020.06.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"2736_CR21","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014. https:\/\/doi.org\/10.1038\/natrevmats.2016.14.","journal-title":"Nat Rev Mater"},{"key":"2736_CR22","doi-asserted-by":"publisher","first-page":"8423","DOI":"10.1021\/acsnano.8b03900","volume":"12","author":"Q Dai","year":"2018","unstructured":"Dai Q, et al. Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors. ACS Nano. 2018;12:8423\u201335. https:\/\/doi.org\/10.1021\/acsnano.8b03900.","journal-title":"ACS Nano"},{"key":"2736_CR23","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41467-017-02191-y","volume":"8","author":"G Zhu","year":"2017","unstructured":"Zhu G, et al. Albumin\/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017;8:1954. https:\/\/doi.org\/10.1038\/s41467-017-02191-y.","journal-title":"Nat Commun"},{"key":"2736_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM, et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20:1578\u201389. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04246.","journal-title":"Nano Lett"},{"key":"2736_CR25","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1073\/pnas.1416159112","volume":"112","author":"A Tzeng","year":"2015","unstructured":"Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci. 2015;112:3320\u20135. https:\/\/doi.org\/10.1073\/pnas.1416159112.","journal-title":"Proc Natl Acad Sci"},{"key":"2736_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell CB, et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nature Biomed Eng. 2018;2:578\u201388. https:\/\/doi.org\/10.1038\/s41551-018-0236-8.","journal-title":"Nature Biomed Eng"},{"key":"2736_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","volume":"14","author":"Q Chen","year":"2018","unstructured":"Chen Q, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2018;14:89\u201397. https:\/\/doi.org\/10.1038\/s41565-018-0319-4.","journal-title":"Nat Nanotechnol"},{"key":"2736_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discovery. 2019;18:175\u201396. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Nat Rev Drug Discovery"},{"key":"2736_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Dane EL. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20:321\u201334. https:\/\/doi.org\/10.1038\/s41577-019-0269-6.","journal-title":"Nat Rev Immunol"},{"key":"2736_CR30","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3390\/curroncol31040157","volume":"31","author":"M Zhang","year":"2024","unstructured":"Zhang M, Sun L, Guo Y, Shi J. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2024;31:2113\u201326. https:\/\/doi.org\/10.3390\/curroncol31040157.","journal-title":"Curr Oncol"},{"key":"2736_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0423","volume":"3","author":"A Haslam","year":"2020","unstructured":"Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020;3:e200423. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0423.","journal-title":"JAMA Netw Open"},{"key":"2736_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1008\u201319. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393.","journal-title":"JAMA Oncol"},{"key":"2736_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168. https:\/\/doi.org\/10.3389\/fimmu.2019.00168.","journal-title":"Front Immunol"},{"key":"2736_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.835502","volume":"12","author":"H Kaplon","year":"2022","unstructured":"Kaplon H. Translational learnings in the development of chemo-immunotherapy combination to bypass the cold tumor microenvironment in pancreatic ductal adenocarcinoma. Front Oncol. 2022;12:835502. https:\/\/doi.org\/10.3389\/fonc.2022.835502.","journal-title":"Front Oncol"},{"key":"2736_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/s0065-2571(00)00013-3","volume":"41","author":"H Maeda","year":"2001","unstructured":"Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001;41:189\u2013207. https:\/\/doi.org\/10.1016\/s0065-2571(00)00013-3.","journal-title":"Adv Enzyme Regul"},{"key":"2736_CR36","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41467-017-01830-8","volume":"8","author":"D Schmid","year":"2017","unstructured":"Schmid D, et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor efficacy. Nat Commun. 2017;8:1747. https:\/\/doi.org\/10.1038\/s41467-017-01830-8.","journal-title":"Nat Commun"},{"key":"2736_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.601497","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, et al. Anti-cancer nanomedicines: a revolution of tumor immunotherapy. Front Immunol. 2020;11:601497. https:\/\/doi.org\/10.3389\/fimmu.2020.601497.","journal-title":"Front Immunol"},{"key":"2736_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.biomaterials.2015.05.002","volume":"61","author":"S Rahimian","year":"2015","unstructured":"Rahimian S, et al. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and toll-like receptor 3 ligand to enhance cancer immunotherapy. Biomaterials. 2015;61:33\u201342. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.05.002.","journal-title":"Biomaterials"},{"key":"2736_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","volume":"99","author":"JS Suk","year":"2016","unstructured":"Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.09.012.","journal-title":"Adv Drug Deliv Rev"},{"key":"2736_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/08982104.2025.2457453","volume":"35","author":"DK Arya","year":"2025","unstructured":"Arya DK, et al. Dual-ligand functionalized liposomes with iRGD\/trastuzumab co-loaded with gefitinib and lycorine for enhanced metastatic breast cancer therapy. J Liposome Res. 2025;35:173\u201387. https:\/\/doi.org\/10.1080\/08982104.2025.2457453.","journal-title":"J Liposome Res"},{"key":"2736_CR41","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1039\/d4na01085j","volume":"7","author":"M Sirazum","year":"2025","unstructured":"Sirazum M, et al. Protein corona composition modulates uptake of polymeric micelles by colorectal cancer cells. Nanoscale Adv. 2025;7:4929\u201346. https:\/\/doi.org\/10.1039\/d4na01085j.","journal-title":"Nanoscale Adv"},{"key":"2736_CR42","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1039\/d4tb02570a","volume":"13","author":"P Pandey","year":"2025","unstructured":"Pandey P, et al. Dual ligand functionalized pH-sensitive liposomes for metastatic breast cancer treatment: in vitro and in vivo assessment. J Mater Chem B. 2025;13:2682\u201394. https:\/\/doi.org\/10.1039\/d4tb02570a.","journal-title":"J Mater Chem B"},{"key":"2736_CR43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12032-024-02504-4","volume":"41","author":"P Pandey","year":"2024","unstructured":"Pandey P, et al. Personalized treatment approach for HER2-positive metastatic breast cancer. Med Oncol. 2024;41:252. https:\/\/doi.org\/10.1007\/s12032-024-02504-4.","journal-title":"Med Oncol"},{"key":"2736_CR44","doi-asserted-by":"publisher","unstructured":"Pandey, P. et al. alphavbeta3 Integrin and Folate-Targeted pH-Sensitive Liposomes with Dual Ligand Modification for Metastatic Breast Cancer Treatment. Bioengineering (Basel). 2024; 11. https:\/\/doi.org\/10.3390\/bioengineering11080800","DOI":"10.3390\/bioengineering11080800"},{"key":"2736_CR45","doi-asserted-by":"publisher","first-page":"8073","DOI":"10.7150\/thno.37198","volume":"9","author":"J Park","year":"2019","unstructured":"Park J, et al. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics. 2019;9:8073\u201390. https:\/\/doi.org\/10.7150\/thno.37198.","journal-title":"Theranostics"},{"key":"2736_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jconrel.2017.07.030","volume":"267","author":"K Park","year":"2017","unstructured":"Park K. The drug delivery field at the inflection point: time to fight its way out of the egg. J Control Release. 2017;267:2\u201314. https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.030.","journal-title":"J Control Release"},{"key":"2736_CR47","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.7150\/thno.49577","volume":"10","author":"Y Shi","year":"2020","unstructured":"Shi Y, van der Meel R, Chen X, Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10:7921\u20134. https:\/\/doi.org\/10.7150\/thno.49577.","journal-title":"Theranostics"},{"key":"2736_CR48","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1158\/1078-0432.Ccr-16-3193","volume":"23","author":"H Lee","year":"2017","unstructured":"Lee H, et al. (64)Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2017;23:4190\u2013202. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3193.","journal-title":"Clin Cancer Res"},{"key":"2736_CR49","doi-asserted-by":"publisher","first-page":"12281","DOI":"10.1021\/acsnano.9b09713","volume":"14","author":"D Sun","year":"2020","unstructured":"Sun D, Zhou S, Gao W. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano. 2020;14:12281\u201390. https:\/\/doi.org\/10.1021\/acsnano.9b09713.","journal-title":"ACS Nano"},{"key":"2736_CR50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2023.07.039","volume":"361","author":"B Lahooti","year":"2023","unstructured":"Lahooti B, et al. Targeting endothelial permeability in the EPR effect. J Control Release. 2023;361:212\u201335. https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.039.","journal-title":"J Control Release"},{"key":"2736_CR51","doi-asserted-by":"publisher","unstructured":"Kim J, Cho H, Lim DK, Joo MK & Kim K. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors. Int J Mol Sci. 2023; 24. https:\/\/doi.org\/10.3390\/ijms241210082","DOI":"10.3390\/ijms241210082"},{"key":"2736_CR52","doi-asserted-by":"publisher","unstructured":"Salvioni L, et al. Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope. Cancers (Basel). 2019; 11. https:\/\/doi.org\/10.3390\/cancers11121855","DOI":"10.3390\/cancers11121855"},{"key":"2736_CR53","doi-asserted-by":"publisher","unstructured":"Subhan MA, Parveen F, Filipczak N, Yalamarty SSK & Torchilin VP. Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis. J Pers Med. 2023; 13. https:\/\/doi.org\/10.3390\/jpm13030389","DOI":"10.3390\/jpm13030389"},{"key":"2736_CR54","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.7150\/thno.37543","volume":"10","author":"G Bort","year":"2020","unstructured":"Bort G, et al. EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: from animal to human with theranostic AGuIX nanoparticles. Theranostics. 2020;10:1319\u201331. https:\/\/doi.org\/10.7150\/thno.37543.","journal-title":"Theranostics"},{"key":"2736_CR55","doi-asserted-by":"publisher","unstructured":"Wei G, Zhang S, Yu S & Lu W. Intravital Microscopy Reveals Endothelial Transcytosis Contributing to Significant Tumor Accumulation of Albumin Nanoparticles. Pharmaceutics. 2023; 15. https:\/\/doi.org\/10.3390\/pharmaceutics15020519","DOI":"10.3390\/pharmaceutics15020519"},{"key":"2736_CR56","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41563-020-0672-1","volume":"19","author":"S Pandit","year":"2020","unstructured":"Pandit S, Dutta D, Nie S. Active transcytosis and new opportunities for cancer nanomedicine. Nat Mater. 2020;19:478\u201380. https:\/\/doi.org\/10.1038\/s41563-020-0672-1.","journal-title":"Nat Mater"},{"key":"2736_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2019.04.031","volume":"303","author":"Q Guo","year":"2019","unstructured":"Guo Q, et al. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases. J Control Release. 2019;303:117\u201329. https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.031.","journal-title":"J Control Release"},{"key":"2736_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202001997","volume":"10","author":"X Ju","year":"2021","unstructured":"Ju X, Miao T, Chen H, Ni J, Han L. Overcoming Mfsd2a-mediated low transcytosis to boost nanoparticle delivery to brain for chemotherapy of brain metastases. Adv Healthc Mater. 2021;10:e2001997. https:\/\/doi.org\/10.1002\/adhm.202001997.","journal-title":"Adv Healthc Mater"},{"key":"2736_CR59","doi-asserted-by":"publisher","unstructured":"Maeda H. The 35th Anniversary of the Discovery of EPR Effect: A New Wave of Nanomedicines for Tumor-Targeted Drug Delivery-Personal Remarks and Future Prospects. J Pers Med. 2021; 11. https:\/\/doi.org\/10.3390\/jpm11030229","DOI":"10.3390\/jpm11030229"},{"key":"2736_CR60","doi-asserted-by":"publisher","unstructured":"Xiao Z, et al. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-\u03baB inhibitor for antitumor immunotherapy. Sci Adv. 2020; 6: eaay7785. https:\/\/doi.org\/10.1126\/sciadv.aay7785","DOI":"10.1126\/sciadv.aay7785"},{"key":"2736_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-025-03396-6","volume":"44","author":"H Xu","year":"2025","unstructured":"Xu H, et al. A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME. J Exp Clin Cancer Res. 2025;44:148. https:\/\/doi.org\/10.1186\/s13046-025-03396-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"2736_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102743","volume":"55","author":"N Gong","year":"2020","unstructured":"Gong N, et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020;55:102743. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102743.","journal-title":"EBioMedicine"},{"key":"2736_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.colcom.2023.100751","volume":"57","author":"X Hua","year":"2023","unstructured":"Hua X, et al. A pH-responsive nanocarrier synergistically activate tumor immunotherapy by promoting pyroptosis and immune checkpoint blocking. Colloid Interface Sci Commun. 2023;57:100751. https:\/\/doi.org\/10.1016\/j.colcom.2023.100751.","journal-title":"Colloid Interface Sci Commun"},{"key":"2736_CR64","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c21823","author":"E Alexander","year":"2026","unstructured":"Alexander E, et al. Nanodiamond-mediated targeted delivery of nanobodies and immunostimulatory RNA for breast cancer therapy. ACS Nano. 2026. https:\/\/doi.org\/10.1021\/acsnano.5c21823.","journal-title":"ACS Nano"},{"key":"2736_CR65","doi-asserted-by":"publisher","unstructured":"Krutzek F, Kopka K & Stadlbauer S. Development of Radiotracers for Imaging of the PD-1\/PD-L1 Axis. Pharmaceuticals (Basel). 2022; 15. https:\/\/doi.org\/10.3390\/ph15060747","DOI":"10.3390\/ph15060747"},{"key":"2736_CR66","doi-asserted-by":"publisher","first-page":"11127","DOI":"10.1021\/acsnano.7b05299","volume":"11","author":"R Meir","year":"2017","unstructured":"Meir R, et al. Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy. ACS Nano. 2017;11:11127\u201334. https:\/\/doi.org\/10.1021\/acsnano.7b05299.","journal-title":"ACS Nano"},{"key":"2736_CR67","doi-asserted-by":"publisher","first-page":"11127","DOI":"10.1021\/acsnano.7b05299","volume":"11","author":"R Meir","year":"2017","unstructured":"Meir R, et al. Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific Immune Cells in Vivo with Biocompatible Fluorescent Nanoparticles. ACS Nano. 2017;11:11127\u201334. https:\/\/doi.org\/10.1021\/acsnano.7b05299.","journal-title":"ACS Nano"},{"key":"2736_CR68","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.ymthe.2017.02.007","volume":"25","author":"L Cheng","year":"2017","unstructured":"Cheng L, Wang Y, Huang L. Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol Ther. 2017;25:1665\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.007.","journal-title":"Mol Ther"},{"key":"2736_CR69","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1038\/s41467-023-42365-5","volume":"14","author":"S Dong","year":"2023","unstructured":"Dong S, et al. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nat Commun. 2023;14:6610. https:\/\/doi.org\/10.1038\/s41467-023-42365-5.","journal-title":"Nat Commun"},{"key":"2736_CR70","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41551-024-01214-6","volume":"8","author":"OPB Wiklander","year":"2024","unstructured":"Wiklander OPB, et al. Antibody-displaying extracellular vesicles for targeted cancer therapy. Nat Biomed Eng. 2024;8:1453\u201368. https:\/\/doi.org\/10.1038\/s41551-024-01214-6.","journal-title":"Nat Biomed Eng"},{"key":"2736_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113138","volume":"42","author":"F Xu","year":"2023","unstructured":"Xu F, et al. Engineering of dendritic cell bispecific extracellular vesicles for tumor-targeting immunotherapy. Cell Rep. 2023;42:113138. https:\/\/doi.org\/10.1016\/j.celrep.2023.113138.","journal-title":"Cell Rep"},{"key":"2736_CR72","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1538-7445.AM2024-1376","volume":"84","author":"R Kandimalla","year":"2024","unstructured":"Kandimalla R, et al. Abstract 1376: engineered exosomes for the delivery of PD-L1 siRNA for lung cancer immunotherapy. Cancer Res. 2024;84:1376\u20131376. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-1376.","journal-title":"Cancer Res"},{"key":"2736_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201801847","volume":"6","author":"Y Mi","year":"2019","unstructured":"Mi Y, Hagan CTt, Vincent BG, Wang AZ. Emerging nano-\/microapproaches for cancer immunotherapy. Adv Sci. 2019;6:1801847. https:\/\/doi.org\/10.1002\/advs.201801847.","journal-title":"Adv Sci"},{"key":"2736_CR74","doi-asserted-by":"publisher","unstructured":"Liu D, Wu D & Li H. Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective. Vaccines (Basel). 2024; 12: 950. https:\/\/doi.org\/10.3390\/vaccines12080950","DOI":"10.3390\/vaccines12080950"},{"key":"2736_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122856","volume":"314","author":"K Poudel","year":"2025","unstructured":"Poudel K, et al. Recent progress in cancer vaccines and nanovaccines. Biomaterials. 2025;314:122856. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122856.","journal-title":"Biomaterials"},{"key":"2736_CR76","doi-asserted-by":"publisher","unstructured":"Lin Z, Chen J & Chen Y. Prospects and Challenges of Lung Cancer Vaccines. Vaccines (Basel). 2025; 13: 836. https:\/\/doi.org\/10.3390\/vaccines13080836","DOI":"10.3390\/vaccines13080836"},{"key":"2736_CR77","doi-asserted-by":"publisher","unstructured":"Luo W, Wang H & Chen L. Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions. Oncol Res. 2025; 33: 1875\u20131893. https:\/\/doi.org\/10.32604\/or.2025.063843","DOI":"10.32604\/or.2025.063843"},{"key":"2736_CR78","doi-asserted-by":"publisher","first-page":"1423212","DOI":"10.3389\/fimmu.2024.1423212","volume":"15","author":"Y Hou","year":"2024","unstructured":"Hou Y, Li Y, Zhang Y, Wu D. Current status and future directions of nanovaccine for cancer: a bibliometric analysis during 2004\u20132023. Front Immunol. 2024;15:1423212. https:\/\/doi.org\/10.3389\/fimmu.2024.1423212.","journal-title":"Front Immunol"},{"key":"2736_CR79","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-024-01628-4","volume":"17","author":"S Liu","year":"2024","unstructured":"Liu S, Wang J, Li M. Personalized nanovaccines for treating solid cancer metastases. J Hematol Oncol. 2024;17:106. https:\/\/doi.org\/10.1186\/s13045-024-01628-4.","journal-title":"J Hematol Oncol"},{"key":"2736_CR80","doi-asserted-by":"publisher","first-page":"1521131","DOI":"10.3389\/fnano.2025.1521131","volume":"7","author":"X Yang","year":"2025","unstructured":"Yang X, Xu T, Huang M, Liu B, Zhang J. Recent advances of nanovaccines on cancer theranostics. Front Nanotechnol. 2025;7:1521131. https:\/\/doi.org\/10.3389\/fnano.2025.1521131.","journal-title":"Front Nanotechnol"},{"key":"2736_CR81","doi-asserted-by":"publisher","unstructured":"Liu M. et al. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy. Sci Adv. 2024; 10: eadk2444. https:\/\/doi.org\/10.1126\/sciadv.adk2444","DOI":"10.1126\/sciadv.adk2444"},{"key":"2736_CR82","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nmat2960","volume":"10","author":"JJ Moon","year":"2011","unstructured":"Moon JJ, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater. 2011;10:243\u201351. https:\/\/doi.org\/10.1038\/nmat2960.","journal-title":"Nat Mater"},{"key":"2736_CR83","doi-asserted-by":"publisher","first-page":"2509880","DOI":"10.1002\/adma.202509880","volume":"37","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang Y, Chen Z, Li X, Wang J. Advances and Strategies in Enhancing mRNA Cancer Vaccines. Adv Mater. 2025;37:2509880. https:\/\/doi.org\/10.1002\/adma.202509880.","journal-title":"Adv Mater"},{"key":"2736_CR84","doi-asserted-by":"publisher","first-page":"60336","DOI":"10.1186\/s12967-024-06033-6","volume":"23","author":"X Li","year":"2025","unstructured":"Li X, Wang Y, Zhang L, Chen J. mRNA vaccines in the context of cancer treatment: from concept to clinical application. J Transl Med. 2025;23:60336. https:\/\/doi.org\/10.1186\/s12967-024-06033-6.","journal-title":"J Transl Med"},{"key":"2736_CR85","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","volume":"17","author":"MA Oberli","year":"2017","unstructured":"Oberli MA, et al. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017;17:1326\u201335. https:\/\/doi.org\/10.1021\/acs.nanolett.6b03329.","journal-title":"Nano Lett"},{"key":"2736_CR86","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s44178-023-00042-z","volume":"2","author":"N Kang","year":"2023","unstructured":"Kang N, Zhang S, Wang Y. A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer. Holist Integr Oncol. 2023;2:18. https:\/\/doi.org\/10.1007\/s44178-023-00042-z.","journal-title":"Holist Integr Oncol"},{"key":"2736_CR87","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"2736_CR88","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10120-025-01640-8","volume":"28","author":"K Nagaoka","year":"2025","unstructured":"Nagaoka K, et al. Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis. Gastric Cancer. 2025;28:825\u201336. https:\/\/doi.org\/10.1007\/s10120-025-01640-8.","journal-title":"Gastric Cancer"},{"key":"2736_CR89","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood-2024-209444","volume":"144","author":"D Dutta","year":"2024","unstructured":"Dutta D, et al. Lipid nanoparticle-mediated combinational mRNA vaccine for multiple myeloma: the next stage of cancer immunotherapy. Blood. 2024;144:3278. https:\/\/doi.org\/10.1182\/blood-2024-209444.","journal-title":"Blood"},{"key":"2736_CR90","doi-asserted-by":"publisher","unstructured":"Zhou L, et al. STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy. Natl Sci Rev. 2023; 10: nwad214. https:\/\/doi.org\/10.1093\/nsr\/nwad214","DOI":"10.1093\/nsr\/nwad214"},{"key":"2736_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202318530","volume":"63","author":"J Liu","year":"2024","unstructured":"Liu J, et al. Synergistic glutathione depletion and STING activation to potentiate dendritic cell maturation and cancer vaccine efficacy. Angew Chem Int Ed Engl. 2024;63:e202318530. https:\/\/doi.org\/10.1002\/anie.202318530.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2736_CR92","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12951-022-01545-z","volume":"20","author":"Z Liao","year":"2022","unstructured":"Liao Z, et al. Self-adjuvanting cancer nanovaccines. J Nanobiotechnol. 2022;20:345. https:\/\/doi.org\/10.1186\/s12951-022-01545-z.","journal-title":"J Nanobiotechnol"},{"key":"2736_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuno.2025.100057","volume":"5","author":"L Wang","year":"2025","unstructured":"Wang L, Chen Y, Zhang X, Li J. Nanoparticles engineering strategies for lymph-node targeted immunotherapy. Immunotherapy Advances. 2025;5:100057. https:\/\/doi.org\/10.1016\/j.immuno.2025.100057.","journal-title":"Immunotherapy Advances"},{"key":"2736_CR94","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/nbt1332","volume":"25","author":"ST Reddy","year":"2007","unstructured":"Reddy ST, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007;25:1159\u201364. https:\/\/doi.org\/10.1038\/nbt1332.","journal-title":"Nat Biotechnol"},{"key":"2736_CR95","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/vaccines13090900","volume":"13","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wang X, Li J, Chen Z. Nanovaccines: Innovative Advances from Design Strategies to Clinical Applications. Vaccines. 2025;13:900. https:\/\/doi.org\/10.3390\/vaccines13090900.","journal-title":"Vaccines"},{"key":"2736_CR96","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. 2018;359:1361\u20135. https:\/\/doi.org\/10.1126\/science.aar6711.","journal-title":"CAR T cell immunotherapy for human cancer"},{"key":"2736_CR97","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40164-024-00576-6","volume":"13","author":"J Pu","year":"2024","unstructured":"Pu J, et al. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. Exp Hematol Oncol. 2024;13:105. https:\/\/doi.org\/10.1186\/s40164-024-00576-6.","journal-title":"Exp Hematol Oncol"},{"key":"2736_CR98","doi-asserted-by":"publisher","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G & Poirot L. 'Off-the-shelf' allogeneic CAR T cells: development and challenges. 2020; 19: 185\u2013199. https:\/\/doi.org\/10.1038\/s41573-019-0051-2","DOI":"10.1038\/s41573-019-0051-2"},{"key":"2736_CR99","doi-asserted-by":"publisher","unstructured":"Martinez M & Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. 2019; 10: 128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128","DOI":"10.3389\/fimmu.2019.00128"},{"key":"2736_CR100","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A. CAR T cells produced in vivo to treat cardiac injury. 2022;375:91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"CAR T cells produced in vivo to treat cardiac injury"},{"key":"2736_CR101","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202310395","volume":"62","author":"E \u00c1lvarez-Benedicto","year":"2023","unstructured":"\u00c1lvarez-Benedicto E, et al. Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma. Angew Chem Int Ed Engl. 2023;62:e202310395. https:\/\/doi.org\/10.1002\/anie.202310395.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2736_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20:e2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"Small"},{"key":"2736_CR103","doi-asserted-by":"publisher","unstructured":"Lemgart V. et al. In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells. Blood. 2024; 144: 3421. https:\/\/doi.org\/10.1182\/blood-2024-207566","DOI":"10.1182\/blood-2024-207566"},{"key":"2736_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11:6080. https:\/\/doi.org\/10.1038\/s41467-020-19486-2.","journal-title":"Nat Commun"},{"key":"2736_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","journal-title":"J Immunother Cancer"},{"key":"2736_CR106","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41565-023-01378-3","volume":"18","author":"X Chen","year":"2023","unstructured":"Chen X, et al. Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours. Nat Nanotechnol. 2023;18:933\u201344. https:\/\/doi.org\/10.1038\/s41565-023-01378-3.","journal-title":"Nat Nanotechnol"},{"key":"2736_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202501475","volume":"15","author":"M Wang","year":"2026","unstructured":"Wang M, et al. Co-delivery of multiple RNAs via lipid nanoparticles enables precise gene editing of CAR-T cells. Adv Healthc Mater. 2026;15:e01475. https:\/\/doi.org\/10.1002\/adhm.202501475.","journal-title":"Adv Healthc Mater"},{"key":"2736_CR108","doi-asserted-by":"publisher","unstructured":"Lu X, et al. A multistep platform identifies spleen-tropic lipid nanoparticles for in vivo T cell-targeted delivery of gene-editing proteins. Sci Adv. 2025; 11: eady5579. https:\/\/doi.org\/10.1126\/sciadv.ady5579","DOI":"10.1126\/sciadv.ady5579"},{"key":"2736_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-026-01040-9","author":"A Rahimi","year":"2026","unstructured":"Rahimi A, Solgi G, Safarzadeh M, Mohammadi P, Rastegari-Pouyani M. Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in solid tumors. Cancer Gene Ther. 2026. https:\/\/doi.org\/10.1038\/s41417-026-01040-9.","journal-title":"Cancer Gene Ther"},{"key":"2736_CR110","doi-asserted-by":"publisher","unstructured":"Khan A, et al. Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies. Front Med (Lausanne). 2026; 13: 1787086. https:\/\/doi.org\/10.3389\/fmed.2026.1787086","DOI":"10.3389\/fmed.2026.1787086"},{"key":"2736_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14061276","author":"VK Yadav","year":"2026","unstructured":"Yadav VK, Yadav P, Mallappa S, Neeli P. In vivo mRNA-lipid nanoparticle CAR-T cell engineering: advances, challenges, and clinical translation. Biomedicines. 2026. https:\/\/doi.org\/10.3390\/biomedicines14061276.","journal-title":"Biomedicines"},{"key":"2736_CR112","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. 2017;68:139\u201352. https:\/\/doi.org\/10.1146\/annurev-med-062315-120245.","journal-title":"CAR T Cell Therapy for Solid Tumors"},{"key":"2736_CR113","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4155\/tde.15.2","volume":"6","author":"RAA Oldham","year":"2015","unstructured":"Oldham RAA, Berinstein EM, Medin JA. Lentiviral vectors in cancer immunotherapy. 2015;6:445\u201361. https:\/\/doi.org\/10.4155\/tde.15.2.","journal-title":"Lentiviral vectors in cancer immunotherapy"},{"key":"2736_CR114","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. 2018;19:723\u201332. https:\/\/doi.org\/10.1038\/s41590-018-0132-0.","journal-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity"},{"key":"2736_CR115","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1158\/1535-7163.Mct-24-0898","volume":"25","author":"M Gao","year":"2026","unstructured":"Gao M, et al. Shaping tumor microenvironment by amplifying the complement cascade for improved immune response in pancreatic cancer model. Mol Cancer Ther. 2026;25:469\u201379. https:\/\/doi.org\/10.1158\/1535-7163.Mct-24-0898.","journal-title":"Mol Cancer Ther"},{"key":"2736_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152380","author":"R Pio","year":"2023","unstructured":"Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. The complement system in cancer: Ambivalence between tumour destruction and promotion. 2023. https:\/\/doi.org\/10.1016\/j.imbio.2023.152380.","journal-title":"The complement system in cancer: Ambivalence between tumour destruction and promotion"},{"key":"2736_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.12.039","author":"J Szebeni","year":"2024","unstructured":"Szebeni J, Storm G, Baranyi L, M\u00e9sz\u00e1ros T, Kozma GT. Complement activation by nanoparticles: Current landscape and future directions. 2024. https:\/\/doi.org\/10.1016\/j.jconrel.2023.12.039.","journal-title":"Complement activation by nanoparticles: Current landscape and future directions"},{"key":"2736_CR118","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12016-019-08741-0","volume":"58","author":"A Bordron","year":"2020","unstructured":"Bordron A, et al. Complement system: a neglected pathway in immunotherapy. Clin Rev Allergy Immunol. 2020;58:155\u201371. https:\/\/doi.org\/10.1007\/s12016-019-08741-0.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2736_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00900-0","author":"DC Mastellos","year":"2024","unstructured":"Mastellos DC, Hajishengallis G, Lambris JD. Complement therapeutics: challenges and opportunities in inflammation and cancer. 2024. https:\/\/doi.org\/10.1038\/s41573-024-00900-0.","journal-title":"Complement therapeutics: challenges and opportunities in inflammation and cancer"},{"key":"2736_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2024.106037","author":"MN Andersen","year":"2024","unstructured":"Andersen MN, H\u00f8nnerup MB, Duggan N, Faber J, S\u00f8rensen BS. Inhibition of the complement alternative pathway triggers cell cycle progression of HaCaT keratinocytes. 2024. https:\/\/doi.org\/10.1016\/j.imlet.2024.106037.","journal-title":"Inhibition of the complement alternative pathway triggers cell cycle progression of HaCaT keratinocytes"},{"key":"2736_CR121","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1021\/acs.molpharmaceut.9b00195","volume":"16","author":"C Li","year":"2019","unstructured":"Li C, et al. Tailored polymers with complement activation ability to improve antitumor immunity. Mol Pharm. 2019;16:2648\u201360. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00195.","journal-title":"Mol Pharm"},{"key":"2736_CR122","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12951-022-01265-4","volume":"20","author":"XY Liu","year":"2022","unstructured":"Liu XY, et al. A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model. J Nanobiotechnology. 2022;20:54. https:\/\/doi.org\/10.1186\/s12951-022-01265-4.","journal-title":"J Nanobiotechnology"},{"key":"2736_CR123","doi-asserted-by":"publisher","unstructured":"Seguin-Devaux, C. et al. Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy. bioRxiv. 2024; 2024.2002.2002.578619. https:\/\/doi.org\/10.1101\/2024.02.02.578619","DOI":"10.1101\/2024.02.02.578619"},{"key":"2736_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115206","author":"T Ji","year":"2024","unstructured":"Ji T, et al. Stimuli-responsive nano-immunostimulants for cancer immunotherapy. 2024. https:\/\/doi.org\/10.1016\/j.addr.2024.115206.","journal-title":"Stimuli-responsive nano-immunostimulants for cancer immunotherapy"},{"key":"2736_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-023-01514-z","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. 2024. https:\/\/doi.org\/10.1038\/s41565-023-01514-z.","journal-title":"Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins"},{"key":"2736_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10378","author":"L Zhou","year":"2023","unstructured":"Zhou L, et al. Redox-responsive branched polymer drug delivery system for mitigation of castrate-resistant prostate cancer. 2023. https:\/\/doi.org\/10.1002\/btm2.10378.","journal-title":"Redox-responsive branched polymer drug delivery system for mitigation of castrate-resistant prostate cancer"},{"key":"2736_CR127","doi-asserted-by":"publisher","unstructured":"Busato D, et al. A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma. 2023; https:\/\/doi.org\/10.1186\/s12967-023-04745-9","DOI":"10.1186\/s12967-023-04745-9"},{"key":"2736_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01695-8","author":"MJ Mitchell","year":"2024","unstructured":"Mitchell MJ. Merging immunotherapy precision with nanomaterial delivery. 2024. https:\/\/doi.org\/10.1038\/s41565-024-01695-8.","journal-title":"Merging immunotherapy precision with nanomaterial delivery"},{"key":"2736_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119221","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, et al. The complement system as a target in cancer immunotherapy. 2023. https:\/\/doi.org\/10.3390\/ijms24119221.","journal-title":"The complement system as a target in cancer immunotherapy"},{"key":"2736_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00655-2","author":"S He","year":"2024","unstructured":"He S, et al. CAR-macrophages for cancer immunotherapy. 2024. https:\/\/doi.org\/10.1038\/s41568-023-00655-2.","journal-title":"CAR-macrophages for cancer immunotherapy"},{"key":"2736_CR131","doi-asserted-by":"publisher","unstructured":"Shao J, et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. 2024; https:\/\/doi.org\/10.1038\/s41591-024-02894-y","DOI":"10.1038\/s41591-024-02894-y"},{"key":"2736_CR132","doi-asserted-by":"publisher","unstructured":"Lin Y, Xu J & Lan H. Nanovaccines empowering CD8+ T cells: a precision strategy to enhance cancer immunotherapy. 2024; https:\/\/doi.org\/10.7150\/thno.93997","DOI":"10.7150\/thno.93997"},{"key":"2736_CR133","doi-asserted-by":"publisher","unstructured":"Kumbhar PR, Kumar P, Lasure A, Velayutham R & Mandal D. An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success. 2023; https:\/\/doi.org\/10.1186\/s11671-023-03913-6","DOI":"10.1186\/s11671-023-03913-6"},{"key":"2736_CR134","doi-asserted-by":"publisher","unstructured":"Chan IH, Bhatia S, Reddy SA & Hamid O. IL-2 based cancer immunotherapies: an evolving paradigm. 2024; 15: 1410295. https:\/\/doi.org\/10.3389\/fimmu.2024.1410295","DOI":"10.3389\/fimmu.2024.1410295"},{"key":"2736_CR135","doi-asserted-by":"publisher","unstructured":"Qu S, et al. Emerging IL-12-based nanomedicine for cancer therapy. 2024; 58: 102331. https:\/\/doi.org\/10.1016\/j.nantod.2024.102331","DOI":"10.1016\/j.nantod.2024.102331"},{"key":"2736_CR136","doi-asserted-by":"publisher","unstructured":"Yang Z, Zhang L & Lu Y. Coordinating interleukin-2 encoding circRNA with immunomodulatory lipid nanoparticles and hydrogel for potent cancer immunotherapy. 2025; 314: 122858. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122858","DOI":"10.1016\/j.biomaterials.2024.122858"},{"key":"2736_CR137","doi-asserted-by":"publisher","unstructured":"Zhao H, Wu S & Liu Q. IL-2-loaded polypeptide nanoparticles for enhanced anti-cancer immunotherapy by modulating T cell differentiation and activation. 2023; 41: 652\u2013663. https:\/\/doi.org\/10.1007\/s10118-023-2898-2","DOI":"10.1007\/s10118-023-2898-2"},{"key":"2736_CR138","doi-asserted-by":"publisher","unstructured":"Li Y, Liu Y & Chen J. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-12 and IL-15 enhances anti-tumor efficacy in mouse models. 2024; 15: 10493. https:\/\/doi.org\/10.1038\/s41467-024-54877-9","DOI":"10.1038\/s41467-024-54877-9"},{"key":"2736_CR139","doi-asserted-by":"publisher","unstructured":"Yang, L., Li, Y. & Bhattacharya, A. Targeted LNPs deliver IL-15 superagonists mRNA for precision immunotherapy. 2024; 310: 122626. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122626","DOI":"10.1016\/j.biomaterials.2024.122626"},{"key":"2736_CR140","doi-asserted-by":"publisher","unstructured":"Niu, L. et al. Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity. 2024; 10: adk7695. https:\/\/doi.org\/10.1126\/sciadv.adk7695","DOI":"10.1126\/sciadv.adk7695"},{"key":"2736_CR141","doi-asserted-by":"publisher","unstructured":"Liu Y, Wu S & Li X. The combination of IL-2 nanoparticles and Palbociclib enhances the anti-tumor immune response for colon cancer therapy. 2024; 15: 1309509. https:\/\/doi.org\/10.3389\/fimmu.2024.1309509","DOI":"10.3389\/fimmu.2024.1309509"},{"key":"2736_CR142","doi-asserted-by":"publisher","first-page":"156","DOI":"10.7150\/ntno.31233","volume":"3","author":"JC Harris","year":"2019","unstructured":"Harris JC, Scully MA, Day ES. Tumor Cell Membrane-Coated Nanoparticles Provide Effective MRI Contrast for Tumor Imaging. 2019;3:156\u201367. https:\/\/doi.org\/10.7150\/ntno.31233.","journal-title":"Tumor Cell Membrane-Coated Nanoparticles Provide Effective MRI Contrast for Tumor Imaging"},{"key":"2736_CR143","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1021\/acsbiomaterials.4c00388","volume":"10","author":"X-P Li","year":"2024","unstructured":"Li X-P, et al. Stimuli-Responsive Nanomaterials for Tumor. Immunotherapy. 2024;10:5474\u201395. https:\/\/doi.org\/10.1021\/acsbiomaterials.4c00388.","journal-title":"Immunotherapy"},{"key":"2736_CR144","doi-asserted-by":"publisher","unstructured":"Sun Y, Zhang J & Li Q. pH-Sensitive Polymeric Nanoparticles for IL-12 Delivery in Tumor Immunotherapy. 2024; 24: 4567\u20134575. https:\/\/doi.org\/10.1021\/acs.nanolett.4c01234","DOI":"10.1021\/acs.nanolett.4c01234"},{"key":"2736_CR145","doi-asserted-by":"publisher","first-page":"1592795","DOI":"10.3389\/fimmu.2025.1592795","volume":"16","author":"R Wang","year":"2025","unstructured":"Wang R, et al. Nanoparticle approaches for manipulating cytokine delivery and neutralization. 2025;16:1592795. https:\/\/doi.org\/10.3389\/fimmu.2025.1592795.","journal-title":"Nanoparticle approaches for manipulating cytokine delivery and neutralization"},{"key":"2736_CR146","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","volume":"24","author":"H Sabit","year":"2025","unstructured":"Sabit H, et al. Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. 2025;24:160. https:\/\/doi.org\/10.1186\/s12943-025-02357-z.","journal-title":"Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery"},{"key":"2736_CR147","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139\u201349. https:\/\/doi.org\/10.1084\/jem.174.1.139.","journal-title":"J Exp Med"},{"key":"2736_CR148","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13046-021-02184-2","volume":"40","author":"A Sharma","year":"2021","unstructured":"Sharma A, Schmidt-Wolf IGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res. 2021;40:388. https:\/\/doi.org\/10.1186\/s13046-021-02184-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"2736_CR149","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7150\/jca.2.363","volume":"2","author":"D Sangiolo","year":"2011","unstructured":"Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363\u20138. https:\/\/doi.org\/10.7150\/jca.2.363.","journal-title":"J Cancer"},{"key":"2736_CR150","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/14712598.2012.675323","volume":"12","author":"G Mesiano","year":"2012","unstructured":"Mesiano G, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673\u201384. https:\/\/doi.org\/10.1517\/14712598.2012.675323.","journal-title":"Expert Opin Biol Ther"},{"key":"2736_CR151","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1517\/14712598.2012.676037","volume":"12","author":"KM Hui","year":"2012","unstructured":"Hui KM. CIK cells\u2013current status, clinical perspectives and future prospects\u2013the good news. Expert Opin Biol Ther. 2012;12:659\u201361. https:\/\/doi.org\/10.1517\/14712598.2012.676037.","journal-title":"Expert Opin Biol Ther"},{"key":"2736_CR152","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1200\/JCO.2023.41.16_suppl.9096","volume":"41","author":"L Liu","year":"2023","unstructured":"Liu L, et al. Long-term outcome for patients with advanced non-small-cell lung cancer treated by autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy: NSCLC-CCICC-002. J Clin Oncol. 2023;41:9096\u20139096. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.9096.","journal-title":"J Clin Oncol"},{"key":"2736_CR153","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006764","volume":"11","author":"CMY Li","year":"2023","unstructured":"Li CMY, et al. Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. J Immunother Cancer. 2023;11:e006764. https:\/\/doi.org\/10.1136\/jitc-2023-006764.","journal-title":"J Immunother Cancer"},{"key":"2736_CR154","doi-asserted-by":"publisher","unstructured":"Chang, S.-C., Ke, T.-W., Chen, W. T.-L., Shyu, W.-C. & Jeng, L.-B. Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case\u2013control comparative study. Front Immunol. 2024; 15 - 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1329615","DOI":"10.3389\/fimmu.2024.1329615"},{"key":"2736_CR155","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41392-024-01788-2","volume":"9","author":"Q-Z Pan","year":"2024","unstructured":"Pan Q-Z, et al. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial. Signal Transduct Target Ther. 2024;9:79. https:\/\/doi.org\/10.1038\/s41392-024-01788-2.","journal-title":"Signal Transduct Target Ther"},{"key":"2736_CR156","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12964-022-00836-0","volume":"20","author":"F Fayyaz","year":"2022","unstructured":"Fayyaz F, Yazdanpanah N, Rezaei N. Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer. Cell Communication and Signaling. 2022;20:41. https:\/\/doi.org\/10.1186\/s12964-022-00836-0.","journal-title":"Cell Communication and Signaling"},{"key":"2736_CR157","doi-asserted-by":"publisher","unstructured":"Moser LM, et al. CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. Front Immunol. 2025; 16 - 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1485817","DOI":"10.3389\/fimmu.2025.1485817"},{"key":"2736_CR158","doi-asserted-by":"publisher","unstructured":"Li C, et al. Cytokine-induced killer cells-mediated chlorin e6-loaded gold nanostars for targeted NIR imaging and immuno-photodynamic combination therapy for lung cancer. Biomed Mater. 2024; 19. https:\/\/doi.org\/10.1088\/1748-605X\/ad580c","DOI":"10.1088\/1748-605X\/ad580c"},{"key":"2736_CR159","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"N Gong","year":"2021","unstructured":"Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16:25\u201336. https:\/\/doi.org\/10.1038\/s41565-020-00822-y.","journal-title":"Nat Nanotechnol"},{"key":"2736_CR160","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202207181","volume":"32","author":"X-Y Zhu","year":"2022","unstructured":"Zhu X-Y, Wang T-Y, Jia H-R, Wu F-G. Immunocyte-derived nanodrugs for cancer therapy. Adv Funct Mater. 2022;32:2207181. https:\/\/doi.org\/10.1002\/adfm.202207181.","journal-title":"Adv Funct Mater"},{"key":"2736_CR161","doi-asserted-by":"publisher","unstructured":"Xu C, Ju D & Zhang X. Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy. Front Immunol. 2022; 13 - 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.923598","DOI":"10.3389\/fimmu.2022.923598"},{"key":"2736_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202200142","volume":"11","author":"Y Du","year":"2022","unstructured":"Du Y, et al. Extracellular vesicle mimetics: preparation from top-down approaches and biological functions. Adv Healthc Mater. 2022;11:2200142. https:\/\/doi.org\/10.1002\/adhm.202200142.","journal-title":"Adv Healthc Mater"},{"key":"2736_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202512333","volume":"22","author":"T Wang","year":"2026","unstructured":"Wang T, et al. An engineered cytokine-induced killer cell-derived nanovesicle featuring multiplexed immune activation performances for enhanced tumor therapy. Small. 2026;22:e12333. https:\/\/doi.org\/10.1002\/smll.202512333.","journal-title":"Small"},{"key":"2736_CR164","doi-asserted-by":"publisher","first-page":"26524","DOI":"10.1002\/ange.202108342","volume":"133","author":"Q-F Meng","year":"2021","unstructured":"Meng Q-F, et al. Genetically programmable fusion cellular vesicles for cancer immunotherapy. Angew Chem. 2021;133:26524\u201330. https:\/\/doi.org\/10.1002\/ange.202108342.","journal-title":"Angew Chem"},{"key":"2736_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12379","volume":"12","author":"L Zhang","year":"2023","unstructured":"Zhang L, et al. Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy. J Extracell Vesicles. 2023;12:12379. https:\/\/doi.org\/10.1002\/jev2.12379.","journal-title":"J Extracell Vesicles"},{"key":"2736_CR166","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400068","volume":"13","author":"Y Pan","year":"2024","unstructured":"Pan Y, et al. Genetically engineered cytomembrane nanovaccines for cancer immunotherapy. Adv Healthc Mater. 2024;13:2400068. https:\/\/doi.org\/10.1002\/adhm.202400068.","journal-title":"Adv Healthc Mater"},{"key":"2736_CR167","doi-asserted-by":"publisher","unstructured":"Zhang, X. et al. PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy. Adv Mat. 2018; 30: 1707112. https:\/\/doi.org\/10.1002\/adma.201707112","DOI":"10.1002\/adma.201707112"},{"key":"2736_CR168","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1038\/s41467-020-18626-y","volume":"11","author":"L Rao","year":"2020","unstructured":"Rao L, et al. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nat Commun. 2020;11:4909. https:\/\/doi.org\/10.1038\/s41467-020-18626-y.","journal-title":"Nat Commun"},{"key":"2736_CR169","doi-asserted-by":"publisher","unstructured":"Su Z. et al. Microfluidics-Enabled Nanovesicle Delivers CD47\/PD-L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma. Adv Sci. 2023; 10: 2206213. https:\/\/doi.org\/10.1002\/advs.202206213","DOI":"10.1002\/advs.202206213"},{"key":"2736_CR170","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41423-023-01031-y","volume":"20","author":"A Sharma","year":"2023","unstructured":"Sharma A, Schmidt-Wolf IGH. Tempering of exhausted T cells to comprehend their adaptive response for suitable clinical translation. Cell Mol Immunol. 2023;20:1401\u20132. https:\/\/doi.org\/10.1038\/s41423-023-01031-y.","journal-title":"Cell Mol Immunol"},{"key":"2736_CR171","doi-asserted-by":"publisher","unstructured":"Wang J, et al. Progenitor-predominant exhaustion in cytokine-induced killers reveals TIM-3 as a superior target for enhancing cytokine-induced killer cytotoxicity. J Leukoc Biol. 2025; 118. https:\/\/doi.org\/10.1093\/jleuko\/qiaf180","DOI":"10.1093\/jleuko\/qiaf180"},{"key":"2736_CR172","doi-asserted-by":"publisher","unstructured":"Kiru L, et al. In vivo imaging of nanoparticle-labeled CAR T cells. Proceedings of the National Academy of Sciences. 2022; 119: e2102363119. https:\/\/doi.org\/10.1073\/pnas.2102363119","DOI":"10.1073\/pnas.2102363119"},{"key":"2736_CR173","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00262-025-04216-8","volume":"74","author":"A Sharma","year":"2025","unstructured":"Sharma A, et al. Advancing CIK cell immunotherapy: highlights from the second international conference on DC-CIK and CAR-CIK approaches. Cancer Immunol Immunother. 2025;74:361. https:\/\/doi.org\/10.1007\/s00262-025-04216-8.","journal-title":"Cancer Immunol Immunother"},{"key":"2736_CR174","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202311471","volume":"63","author":"X Duan","year":"2024","unstructured":"Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed Engl. 2024;63:e202311471. https:\/\/doi.org\/10.1002\/anie.202311471.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2736_CR175","doi-asserted-by":"publisher","unstructured":"Kciuk M, et al. Targeting the tumor microenvironment - a new immunotherapeutic approach for prostate cancer. Biomol Biomed. 2024; 24: 676\u2013691. https:\/\/doi.org\/10.17305\/bb.2023.9715","DOI":"10.17305\/bb.2023.9715"},{"key":"2736_CR176","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202207432","volume":"10","author":"Z Li","year":"2023","unstructured":"Li Z, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the efficacy of cancer immunotherapy. Adv Sci. 2023;10:e2207432. https:\/\/doi.org\/10.1002\/advs.202207432.","journal-title":"Adv Sci"},{"key":"2736_CR177","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jconrel.2024.03.056","volume":"369","author":"J Zhou","year":"2024","unstructured":"Zhou J, et al. Tumor-associated macrophage membrane-coated biomimetic nanoparticles enhance autophagy blockade and chemosensitivity in breast cancer. J Control Release. 2024;369:550\u201364. https:\/\/doi.org\/10.1016\/j.jconrel.2024.03.056.","journal-title":"J Control Release"},{"key":"2736_CR178","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41392-023-01450-3","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. mRNA Delivery of a Bispecific Single-Domain Antibody Construct Drives Effective Tumor Regression. Signal Transduct Target Ther. 2023;8:187. https:\/\/doi.org\/10.1038\/s41392-023-01450-3.","journal-title":"Signal Transduct Target Ther"},{"key":"2736_CR179","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12951-024-02529-x","volume":"22","author":"J Li","year":"2024","unstructured":"Li J, et al. Neutrophil-membrane-coated deoxygenated nanozyme-mediated oxygen delivery system for COVID-19-related ARDS therapy. J Nanobiotechnol. 2024;22:252. https:\/\/doi.org\/10.1186\/s12951-024-02529-x.","journal-title":"J Nanobiotechnol"},{"key":"2736_CR180","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3:1452\u201363. https:\/\/doi.org\/10.1038\/s43018-022-00468-w.","journal-title":"Nat Cancer"},{"key":"2736_CR181","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.49","volume":"2","author":"X Fan","year":"2023","unstructured":"Fan X, et al. cGAS-STING signaling in cancer: regulation and therapeutic targeting. MedComm-Oncol. 2023;2:e49. https:\/\/doi.org\/10.1002\/mog2.49.","journal-title":"MedComm-Oncol"},{"key":"2736_CR182","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1021\/acs.nanolett.2c00185","volume":"22","author":"H Xia","year":"2022","unstructured":"Xia H, et al. A pH-\/enzyme-responsive nanoparticle selectively targets endosomal toll-like receptors to potentiate robust cancer vaccination. Nano Lett. 2022;22:2978\u201387. https:\/\/doi.org\/10.1021\/acs.nanolett.2c00185.","journal-title":"Nano Lett"},{"key":"2736_CR183","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","volume":"81","author":"G Li","year":"2024","unstructured":"Li G, et al. cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors. Cell Mol Life Sci. 2024;81:149. https:\/\/doi.org\/10.1007\/s00018-024-05191-6.","journal-title":"Cell Mol Life Sci"},{"key":"2736_CR184","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202304845","volume":"36","author":"D Liu","year":"2024","unstructured":"Liu D, et al. Tumor microenvironment-responsive nanoparticles amplifying STING signaling pathway for cancer immunotherapy. Adv Mater. 2024;36:e2304845. https:\/\/doi.org\/10.1002\/adma.202304845.","journal-title":"Adv Mater"},{"key":"2736_CR185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887649","volume":"13","author":"JR Podojil","year":"2022","unstructured":"Podojil JR, et al. Biodegradable nanoparticles induce cGAS\/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy. Front Immunol. 2022;13:887649. https:\/\/doi.org\/10.3389\/fimmu.2022.887649.","journal-title":"Front Immunol"},{"key":"2736_CR186","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1039\/d2sc06036a","volume":"14","author":"L Cai","year":"2023","unstructured":"Cai L, et al. Manganese(ii) complexes stimulate antitumor immunity via aggravating DNA damage and activating the cGAS-STING pathway. Chem Sci. 2023;14:4375\u201389. https:\/\/doi.org\/10.1039\/d2sc06036a.","journal-title":"Chem Sci"},{"key":"2736_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2022.101405","volume":"43","author":"H Tian","year":"2022","unstructured":"Tian H, et al. Manganese-phenolic nanoadjuvant combines sonodynamic therapy with cGAS-STING activation for enhanced cancer immunotherapy. Nano Today. 2022;43:101405. https:\/\/doi.org\/10.1016\/j.nantod.2022.101405.","journal-title":"Nano Today"},{"key":"2736_CR188","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s12951-024-02809-6","volume":"22","author":"X Liang","year":"2024","unstructured":"Liang X, et al. Tumor microenvironment-responsive manganese-based nano-modulator activate the cGAS-STING pathway to enhance innate immune system response. J Nanobiotechnology. 2024;22:535. https:\/\/doi.org\/10.1186\/s12951-024-02809-6.","journal-title":"J Nanobiotechnology"},{"key":"2736_CR189","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1016\/j.apsb.2024.04.028","volume":"14","author":"C Yan","year":"2024","unstructured":"Yan C, Lv H, Feng Y, Li Y, Zhao Z. Inhalable nanoparticles with enhanced cuproptosis and cGAS-STING activation for synergistic lung metastasis immunotherapy. Acta Pharm Sin B. 2024;14:3697\u2013710. https:\/\/doi.org\/10.1016\/j.apsb.2024.04.028.","journal-title":"Acta Pharm Sin B"},{"key":"2736_CR190","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202208782","volume":"35","author":"S Lugani","year":"2023","unstructured":"Lugani S, et al. Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti-Tumor Immunity in Murine Glioblastoma. Adv Mater. 2023;35:e2208782. https:\/\/doi.org\/10.1002\/adma.202208782.","journal-title":"Adv Mater"},{"key":"2736_CR191","doi-asserted-by":"publisher","first-page":"23757","DOI":"10.1021\/acsnano.4c08811","volume":"18","author":"Y Ota","year":"2024","unstructured":"Ota Y, et al. Targeting tumor-associated macrophages with the immune-activating nanomedicine for achieving strong antitumor activity with rapid clearance from the body. ACS Nano. 2024;18:23757\u201372. https:\/\/doi.org\/10.1021\/acsnano.4c08811.","journal-title":"ACS Nano"},{"key":"2736_CR192","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1021\/acs.molpharmaceut.0c00271","volume":"17","author":"H Kim","year":"2020","unstructured":"Kim H, et al. TLR7\/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy. Mol Pharm. 2020;17:2109\u201324. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00271.","journal-title":"Mol Pharm"},{"key":"2736_CR193","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202830","volume":"12","author":"E Choi","year":"2023","unstructured":"Choi E, et al. Nanoscale Hafnium Metal-Organic Frameworks Enhance Radiotherapeutic Effects by Upregulation of Type I Interferon and TLR7 Expression. Adv Healthc Mater. 2023;12:e2202830. https:\/\/doi.org\/10.1002\/adhm.202202830.","journal-title":"Adv Healthc Mater"},{"key":"2736_CR194","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.actbio.2025.08.021","volume":"204","author":"P Wang","year":"2025","unstructured":"Wang P, et al. MIL-100(Fe)-based co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway. Acta Biomater. 2025;204:582\u201395. https:\/\/doi.org\/10.1016\/j.actbio.2025.08.021.","journal-title":"Acta Biomater"},{"key":"2736_CR195","doi-asserted-by":"publisher","first-page":"1093240","DOI":"10.3389\/fonc.2022.1093240","volume":"12","author":"S Chen","year":"2022","unstructured":"Chen S, Peng A, Chen M, Zhan M. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy. Front Oncol. 2022;12:1093240. https:\/\/doi.org\/10.3389\/fonc.2022.1093240.","journal-title":"Front Oncol"},{"key":"2736_CR196","doi-asserted-by":"publisher","first-page":"13375","DOI":"10.1021\/acsami.4c18570","volume":"17","author":"H Chen","year":"2025","unstructured":"Chen H, et al. Augmenting antitumor immune effects through the coactivation of cGAS-STING and NF-\u03baB crosstalk in dendritic cells and macrophages by engineered manganese ferrite nanohybrids. ACS Appl Mater Interfaces. 2025;17:13375\u201390. https:\/\/doi.org\/10.1021\/acsami.4c18570.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2736_CR197","doi-asserted-by":"publisher","first-page":"15449","DOI":"10.1021\/acsnano.3c01215","volume":"17","author":"G Luo","year":"2023","unstructured":"Luo G, et al. Multifunctional calcium-manganese nanomodulator provides antitumor treatment and improved immunotherapy via reprogramming of the tumor microenvironment. ACS Nano. 2023;17:15449\u201365. https:\/\/doi.org\/10.1021\/acsnano.3c01215.","journal-title":"ACS Nano"},{"key":"2736_CR198","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202309202","volume":"20","author":"H Wang","year":"2024","unstructured":"Wang H, et al. Near-Infrared Light-Driven Nanoparticles for Cancer Photoimmunotherapy by Synergizing Immune Cell Death and Epigenetic Regulation. Small. 2024;20:e2309202. https:\/\/doi.org\/10.1002\/smll.202309202.","journal-title":"Small"},{"key":"2736_CR199","doi-asserted-by":"publisher","first-page":"13226","DOI":"10.1021\/acsnano.4c02337","volume":"18","author":"J Li","year":"2024","unstructured":"Li J, et al. Triune nanomodulator enables exhausted cytotoxic T lymphocyte rejuvenation for cancer epigenetic immunotherapy. ACS Nano. 2024;18:13226\u201340. https:\/\/doi.org\/10.1021\/acsnano.4c02337.","journal-title":"ACS Nano"},{"key":"2736_CR200","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41565-021-00972-7","volume":"16","author":"Y Zhai","year":"2021","unstructured":"Zhai Y, et al. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nat Nanotechnol. 2021;16:1271\u201380. https:\/\/doi.org\/10.1038\/s41565-021-00972-7.","journal-title":"Nat Nanotechnol"},{"key":"2736_CR201","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jconrel.2023.11.011","volume":"364","author":"W Chen","year":"2023","unstructured":"Chen W, et al. Remodeling the tumor microenvironment with core-shell nanosystems for enhanced synergistic cancer therapy. J Control Release. 2023;364:614\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2023.11.011.","journal-title":"J Control Release"},{"key":"2736_CR202","doi-asserted-by":"publisher","first-page":"1291478","DOI":"10.3389\/fimmu.2023.1291478","volume":"14","author":"S He","year":"2023","unstructured":"He S, et al. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and engineered \u201csuper\u201d macrophages. Front Immunol. 2023;14:1291478. https:\/\/doi.org\/10.3389\/fimmu.2023.1291478.","journal-title":"Front Immunol"},{"key":"2736_CR203","doi-asserted-by":"publisher","first-page":"1432189","DOI":"10.3389\/fbioe.2024.1432189","volume":"12","author":"K Jiang","year":"2024","unstructured":"Jiang K, et al. Advances in magnetic induction hyperthermia: a comprehensive review in tumor metabolism and immunology. Front Bioeng Biotechnol. 2024;12:1432189. https:\/\/doi.org\/10.3389\/fbioe.2024.1432189.","journal-title":"Front Bioeng Biotechnol"},{"key":"2736_CR204","doi-asserted-by":"publisher","first-page":"1258786","DOI":"10.3389\/fimmu.2023.1258786","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, et al. Amplifying cancer treatment: advances in tumor immunotherapy and hyperthermia. Front Immunol. 2023;14:1258786. https:\/\/doi.org\/10.3389\/fimmu.2023.1258786.","journal-title":"Front Immunol"},{"key":"2736_CR205","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00262-022-03345-8","volume":"72","author":"A Nishikawa","year":"2023","unstructured":"Nishikawa A, Suzuki Y, Kaneko M, Ito A. Combination of magnetic hyperthermia and immunomodulators to drive complete tumor regression of poorly immunogenic melanoma. Cancer Immunol Immunother. 2023;72:1493\u2013504. https:\/\/doi.org\/10.1007\/s00262-022-03345-8.","journal-title":"Cancer Immunol Immunother"},{"key":"2736_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102070","volume":"33","author":"M Yang","year":"2025","unstructured":"Yang M, et al. Magnetic hyperthermia in oncology: nanomaterials-driven combinatorial strategies for synergistic therapeutic gains. Mater Today Bio. 2025;33:102070. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102070.","journal-title":"Mater Today Bio"},{"key":"2736_CR207","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41467-025-55876-0","volume":"16","author":"C Li","year":"2025","unstructured":"Li C, et al. CD133+PD-L1+ cancer cells confer resistance to adoptively transferred engineered macrophage-based therapy in melanoma. Nat Commun. 2025;16:58. https:\/\/doi.org\/10.1038\/s41467-025-55876-0.","journal-title":"Nat Commun"},{"key":"2736_CR208","doi-asserted-by":"publisher","unstructured":"McGahan BG, et al. Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Cancer. Nanomaterials (Basel). 2025; 15: 702. https:\/\/doi.org\/10.3390\/nano15040702","DOI":"10.3390\/nano15040702"},{"key":"2736_CR209","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/pharmaceutics15010100","volume":"15","author":"M C\u00e2ndido","year":"2023","unstructured":"C\u00e2ndido M, Vieira P, Campos A, Soares C, Raniero L. Gold-Coated Superparamagnetic Iron Oxide Nanoparticles Functionalized to EGF and Ce6 Complexes for Breast Cancer Diagnoses and Therapy. Pharmaceutics. 2023;15:100. https:\/\/doi.org\/10.3390\/pharmaceutics15010100.","journal-title":"Pharmaceutics"},{"key":"2736_CR210","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202500260","volume":"14","author":"Y Gao","year":"2025","unstructured":"Gao Y, Wang J, Zheng J. All-in-one magnetic nanoparticles for thermo-immunotherapy of melanoma. Adv Healthc Mater. 2025;14:e2500260. https:\/\/doi.org\/10.1002\/adhm.202500260.","journal-title":"Adv Healthc Mater"},{"key":"2736_CR211","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"N Li","year":"2023","unstructured":"Li N, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20:432\u201347. https:\/\/doi.org\/10.1038\/s41423-023-00990-6.","journal-title":"Cell Mol Immunol"},{"key":"2736_CR212","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fimmu.2019.00279","volume":"10","author":"W van Eden","year":"2019","unstructured":"van Eden W, et al. Heat Shock Proteins Can Be Surrogate Autoantigens for Induction of Antigen Specific Therapeutic Tolerance in Rheumatoid Arthritis. Front Immunol. 2019;10:279. https:\/\/doi.org\/10.3389\/fimmu.2019.00279.","journal-title":"Front Immunol"},{"key":"2736_CR213","doi-asserted-by":"publisher","unstructured":"Luksik, A. S., Yazigi, E., Shah, P. & Jackson, C. M. CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. Cancers (Basel). 2023; 15: 1414. https:\/\/doi.org\/10.3390\/cancers15051414","DOI":"10.3390\/cancers15051414"},{"key":"2736_CR214","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202305459","volume":"10","author":"X Liu","year":"2023","unstructured":"Liu X, Wang Y, Wang X. New Types of Magnetic Nanoparticles for Stimuli-Responsive Theranostics: Beyond Common Designs. Adv Sci. 2023;10:e2305459. https:\/\/doi.org\/10.1002\/advs.202305459.","journal-title":"Adv Sci"},{"key":"2736_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.100943","volume":"26","author":"Z Hu","year":"2025","unstructured":"Hu Z, et al. pH-responsive magnetic Fe3O4 modified chitosan nanoparticles for targeted delivery of ursolic acid to colorectal cancer cells. Materials Today Bio. 2025;26:100943. https:\/\/doi.org\/10.1016\/j.mtbio.2025.100943.","journal-title":"Materials Today Bio"},{"key":"2736_CR216","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41467-024-44963-3","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, et al. Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy. Nat Commun. 2024;15:332. https:\/\/doi.org\/10.1038\/s41467-024-44963-3.","journal-title":"Nat Commun"},{"key":"2736_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202403059","volume":"13","author":"A Kumar","year":"2024","unstructured":"Kumar A, Kumar P, Singh A. Advanced nanomaterials for cancer therapy: gold, silver, and iron oxide nanoparticles. Adv Healthc Mater. 2024;13:e2403059. https:\/\/doi.org\/10.1002\/adhm.202403059.","journal-title":"Adv Healthc Mater"},{"key":"2736_CR218","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jconrel.2024.03.055","volume":"369","author":"SLC Pinho","year":"2024","unstructured":"Pinho SLC, Pereira GA, Voisin P. Simple thermal treatment to improve the MRI and magnetic hyperthermia performance of hybrid iron oxide nanocubes. J Control Release. 2024;369:550\u201364. https:\/\/doi.org\/10.1016\/j.jconrel.2024.03.055.","journal-title":"J Control Release"},{"key":"2736_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2025.213926","volume":"35","author":"X Zhang","year":"2025","unstructured":"Zhang X, Li J, Wang Y. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery: recent advances and future perspectives. Bioact Mater. 2025;35:213926. https:\/\/doi.org\/10.1016\/j.bioactmat.2025.213926.","journal-title":"Bioact Mater"},{"key":"2736_CR220","doi-asserted-by":"publisher","first-page":"1344272","DOI":"10.3389\/fimmu.2024.1344272","volume":"15","author":"L Chen","year":"2024","unstructured":"Chen L, Zhang Y, Li W. Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors and magnetic hyperthermia therapy. Front Immunol. 2024;15:1344272. https:\/\/doi.org\/10.3389\/fimmu.2024.1344272.","journal-title":"Front Immunol"},{"key":"2736_CR221","doi-asserted-by":"publisher","unstructured":"O'Rourke DM, Nasrallah MP & Desai A. Pre-Clinical Models for CAR T-Cell Therapy for Glioma. Cancers (Basel). 2024; 16: 3082. https:\/\/doi.org\/10.3390\/cancers16173082","DOI":"10.3390\/cancers16173082"},{"key":"2736_CR222","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/neuonc\/noae135","volume":"26","author":"KS Kim","year":"2024","unstructured":"Kim KS, et al. Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: a novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024;26:2044\u201360. https:\/\/doi.org\/10.1093\/neuonc\/noae135.","journal-title":"Neuro Oncol"},{"key":"2736_CR223","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.799026","volume":"13","author":"J Shao","year":"2022","unstructured":"Shao J, et al. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Front Immunol. 2022;13:799026. https:\/\/doi.org\/10.3389\/fimmu.2022.799026.","journal-title":"Front Immunol"},{"key":"2736_CR224","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12032-025-03020-9","volume":"42","author":"P Rana","year":"2025","unstructured":"Rana P, et al. Magnetic hyperthermia-based therapies for cancer targeting: current progress and future perspectives. Med Oncol. 2025;42:453. https:\/\/doi.org\/10.1007\/s12032-025-03020-9.","journal-title":"Med Oncol"},{"key":"2736_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2025.100509","volume":"43","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhang H, Li J. Advancements in antibody-drug conjugates as cancer therapeutics. Drug Discov Today Technol. 2025;43:100509. https:\/\/doi.org\/10.1016\/j.ddtec.2025.100509.","journal-title":"Drug Discov Today Technol"},{"key":"2736_CR226","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-024-02214-5","volume":"23","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang Y, Zhang H. Present and future of cancer nano-immunotherapy. Mol Cancer. 2024;23:14. https:\/\/doi.org\/10.1186\/s12943-024-02214-5.","journal-title":"Mol Cancer"},{"key":"2736_CR227","doi-asserted-by":"publisher","first-page":"1516419","DOI":"10.3389\/fimmu.2025.1516419","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Li Y, Wang X. Antibody-drug conjugates in cancer therapy: applications and future directions. Front Immunol. 2025;16:1516419. https:\/\/doi.org\/10.3389\/fimmu.2025.1516419.","journal-title":"Front Immunol"},{"key":"2736_CR228","doi-asserted-by":"publisher","unstructured":"Kim S, Lee J & Park H. Opportunities and Challenges in Antibody\u2013Drug Conjugates for Cancer Therapy. Cancers (Basel). 2024; 16: 3185. https:\/\/doi.org\/10.3390\/cancers16183185","DOI":"10.3390\/cancers16183185"},{"key":"2736_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101056","volume":"26","author":"Q Chen","year":"2025","unstructured":"Chen Q, Wang L, Zhang Y. Nanotechnology-based drug delivery for breast cancer treatment. Mater Today Bio. 2025;26:101056. https:\/\/doi.org\/10.1016\/j.mtbio.2025.101056.","journal-title":"Mater Today Bio"},{"key":"2736_CR230","doi-asserted-by":"publisher","DOI":"10.1002\/nano.202300191","volume":"5","author":"M Li","year":"2024","unstructured":"Li M, Zhang X, Wang Y. Trastuzumab-based nanomedicines for breast cancer therapy: recent progress and perspectives. Nano Select. 2024;5:e202300191. https:\/\/doi.org\/10.1002\/nano.202300191.","journal-title":"Nano Select"},{"key":"2736_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.116310","volume":"232","author":"C Zhang","year":"2023","unstructured":"Zhang C, Li J, Wang H. Targeted therapy of breast tumor by PLGA-based nanostructures: the versatile function in doxorubicin delivery. Environ Res. 2023;232:116310. https:\/\/doi.org\/10.1016\/j.envres.2023.116310.","journal-title":"Environ Res"},{"key":"2736_CR232","doi-asserted-by":"publisher","first-page":"1464584","DOI":"10.3389\/fbioe.2024.1464584","volume":"12","author":"X Liu","year":"2024","unstructured":"Liu X, Wang Y, Zhang L. Nanomaterials: breaking the bottleneck of breast cancer drug delivery. Front Bioeng Biotechnol. 2024;12:1464584. https:\/\/doi.org\/10.3389\/fbioe.2024.1464584.","journal-title":"Front Bioeng Biotechnol"},{"key":"2736_CR233","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1039\/d4na00086b","volume":"6","author":"H Kim","year":"2024","unstructured":"Kim H, Park S, Lee J. Cutting-edge approaches for targeted drug delivery in breast cancer. Nanoscale Adv. 2024;6:2536\u201361. https:\/\/doi.org\/10.1039\/d4na00086b.","journal-title":"Nanoscale Adv"},{"key":"2736_CR234","doi-asserted-by":"publisher","unstructured":"Wang Z, Li Y & Zhang H. Exploring Experimental and In Silico Approaches for Antibody\u2013Drug Conjugates. Pharmaceuticals (Basel). 2025; 18: 1198. https:\/\/doi.org\/10.3390\/ph18081198","DOI":"10.3390\/ph18081198"},{"key":"2736_CR235","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12672-025-01820-z","volume":"16","author":"S Lee","year":"2025","unstructured":"Lee S, Kim J, Park H. Maytansinoids in cancer therapy: advancements in antibody\u2013drug conjugates and nanotechnology-enhanced drug delivery systems. Discov Oncol. 2025;16:5. https:\/\/doi.org\/10.1007\/s12672-025-01820-z.","journal-title":"Discov Oncol"},{"key":"2736_CR236","doi-asserted-by":"publisher","unstructured":"Chen Q, Zhang L & Wang Y. Antibody nanoparticle conjugate\u2013based targeted immunotherapy for non-small cell lung cancer. Sci Adv. 2024; 10: adi2046. https:\/\/doi.org\/10.1126\/sciadv.adi2046","DOI":"10.1126\/sciadv.adi2046"},{"key":"2736_CR237","doi-asserted-by":"publisher","first-page":"1095598","DOI":"10.3389\/fchem.2023.1095598","volume":"11","author":"J Li","year":"2023","unstructured":"Li J, Wang H, Zhang Y. \u201cSmart\u201d drug delivery: A window to future of translational medicine. Front Chem. 2023;11:1095598. https:\/\/doi.org\/10.3389\/fchem.2023.1095598.","journal-title":"Front Chem"},{"key":"2736_CR238","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/biomedicines12071491","volume":"12","author":"S Kim","year":"2024","unstructured":"Kim S, Lee J, Park H. Antibody-Drug Conjugates to Promote Immune Surveillance. Biomedicines. 2024;12:1491. https:\/\/doi.org\/10.3390\/biomedicines12071491.","journal-title":"Biomedicines"},{"key":"2736_CR239","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/pharmaceutics16091146","volume":"16","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li Z, Zhang H. Synergizing Immunotherapy and Antibody-Drug Conjugates: New Horizons in Cancer Treatment. Pharmaceutics. 2024;16:1146. https:\/\/doi.org\/10.3390\/pharmaceutics16091146.","journal-title":"Pharmaceutics"},{"key":"2736_CR240","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"key":"2736_CR241","doi-asserted-by":"publisher","first-page":"2505349","DOI":"10.1080\/21645515.2025.2505349","volume":"21","author":"X Zhang","year":"2025","unstructured":"Zhang X, Li Y, Wang H. How has the field of immunogenic cell death in breast cancer evolved in the last decade? Insights from literature analysis. Hum Vaccin Immunother. 2025;21:2505349. https:\/\/doi.org\/10.1080\/21645515.2025.2505349.","journal-title":"Hum Vaccin Immunother"},{"key":"2736_CR242","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2023.09.021","volume":"364","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Li J, Wang H. The role of nanotechnology in enhancing cancer immunotherapy: A review. J Control Release. 2023;364:34\u201354. https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.021.","journal-title":"J Control Release"},{"key":"2736_CR243","doi-asserted-by":"publisher","unstructured":"Kim J, Lee S & Park H. Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A Comprehensive Review. Vaccines (Basel). 2025; 13: 612. https:\/\/doi.org\/10.3390\/vaccines13060612","DOI":"10.3390\/vaccines13060612"},{"key":"2736_CR244","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cpt.2024.10.001","volume":"3","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li J, Zhang H. Advances in nanoparticle-mediated cancer therapeutics. Cancer Pathog Ther. 2025;3:322\u201336. https:\/\/doi.org\/10.1016\/j.cpt.2024.10.001.","journal-title":"Cancer Pathog Ther"},{"key":"2736_CR245","doi-asserted-by":"publisher","unstructured":"Kim S, Lee J & Park H. Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology Strategies. Pharmaceuticals (Basel). 2025; 18: 1086. https:\/\/doi.org\/10.3390\/ph18081086","DOI":"10.3390\/ph18081086"},{"key":"2736_CR246","doi-asserted-by":"publisher","first-page":"1479993","DOI":"10.3389\/fnano.2024.1479993","volume":"6","author":"Q Chen","year":"2024","unstructured":"Chen Q, Wang L, Zhang Y. Clinical applications and therapeutic potentials of advanced nanoparticles in oncology. Front Nanotechnol. 2024;6:1479993. https:\/\/doi.org\/10.3389\/fnano.2024.1479993.","journal-title":"Front Nanotechnol"},{"key":"2736_CR247","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","volume":"24","author":"M Li","year":"2025","unstructured":"Li M, Zhang X, Wang Y. Advances in cancer immunotherapy: historical perspectives, current status, and future innovations. Mol Cancer. 2025;24:205. https:\/\/doi.org\/10.1186\/s12943-025-02410-x.","journal-title":"Mol Cancer"},{"key":"2736_CR248","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"L Zhang","year":"2024","unstructured":"Zhang L, Li Y, Wang X. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9:201. https:\/\/doi.org\/10.1038\/s41392-024-01889-y.","journal-title":"Signal Transduct Target Ther"},{"key":"2736_CR249","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202423280","volume":"64","author":"X Liu","year":"2025","unstructured":"Liu X, Wang Y, Zhang L. Innate immune activation with multifunctional nanoparticles for cancer immunotherapy. Angew Chem Int Ed Engl. 2025;64:e202423280. https:\/\/doi.org\/10.1002\/anie.202423280.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2736_CR250","doi-asserted-by":"publisher","unstructured":"Kim H, Park S & Lee J. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024; 21: 807\u2013824. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0055","DOI":"10.20892\/j.issn.2095-3941.2024.0055"},{"key":"2736_CR251","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s13346-024-01509-2","volume":"14","author":"Z Wang","year":"2024","unstructured":"Wang Z, Li Y, Zhang H. Nano drug delivery systems for advanced immune checkpoint inhibitor therapy. Drug Deliv Transl Res. 2024;14:2645\u201367. https:\/\/doi.org\/10.1007\/s13346-024-01509-2.","journal-title":"Drug Deliv Transl Res"},{"key":"2736_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104374","volume":"199","author":"S Lee","year":"2025","unstructured":"Lee S, Kim J, Park H. Recent advances in nanoparticles with a PD-L1-based therapy for lung cancer. Crit Rev Oncol Hematol. 2025;199:104374. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104374.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2736_CR253","doi-asserted-by":"publisher","first-page":"6038","DOI":"10.1200\/JCO.2023.41.16_suppl.6038","volume":"41","author":"C Shen","year":"2023","unstructured":"Shen C, et al. Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC. J Clin Oncol. 2023;41:6038\u20136038. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.6038.","journal-title":"J Clin Oncol"},{"key":"2736_CR254","doi-asserted-by":"publisher","first-page":"33366","DOI":"10.1021\/acsnano.4c08448","volume":"19","author":"M Li","year":"2025","unstructured":"Li M, Zhang X, Wang Y. Nanovaccines for cancer immunotherapy: mechanisms and clinical applications. ACS Nano. 2025;19:33366\u201380. https:\/\/doi.org\/10.1021\/acsnano.4c08448.","journal-title":"ACS Nano"},{"key":"2736_CR255","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102070","volume":"33","author":"L Zhang","year":"2025","unstructured":"Zhang L, Li Y, Wang X. Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical perspectives. Mater Today Bio. 2025;33:102070. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102070.","journal-title":"Mater Today Bio"},{"key":"2736_CR256","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/s0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(23)02268-7.","journal-title":"Lancet"},{"key":"2736_CR257","doi-asserted-by":"publisher","first-page":"1808146","DOI":"10.3389\/fimmu.2026.1808146","volume":"17","author":"X Yu","year":"2026","unstructured":"Yu X, Fu K. Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy. Front Immunol. 2026;17:1808146. https:\/\/doi.org\/10.3389\/fimmu.2026.1808146.","journal-title":"Front Immunol"},{"key":"2736_CR258","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"2736_CR259","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202100429","volume":"33","author":"MM Billingsley","year":"2021","unstructured":"Billingsley MM, et al. mRNA delivery to T cells for adoptive immunotherapy. Adv Mater. 2021;33:e2100429. https:\/\/doi.org\/10.1002\/adma.202100429.","journal-title":"Adv Mater"},{"key":"2736_CR260","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","volume":"12","author":"E Degagne","year":"2024","unstructured":"Degagne E, et al. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models. Cancer Immunol Res. 2024;12:462\u201377. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0679.","journal-title":"Cancer Immunol Res"},{"key":"2736_CR261","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jir.2018.0019","volume":"39","author":"KC Conlon","year":"2019","unstructured":"Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer. J Interferon Cytokine Res. 2019;39:6\u201321. https:\/\/doi.org\/10.1089\/jir.2018.0019.","journal-title":"J Interferon Cytokine Res"},{"key":"2736_CR262","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","volume":"10","author":"A Diab","year":"2020","unstructured":"Diab A, et al. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov. 2020;10:1158\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1510.","journal-title":"Cancer Discov"},{"key":"2736_CR263","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13073-021-00940-9","volume":"13","author":"D Srikrishna","year":"2021","unstructured":"Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome Med. 2021;13:120. https:\/\/doi.org\/10.1186\/s13073-021-00940-9.","journal-title":"Genome Med"},{"key":"2736_CR264","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","volume":"177","author":"M Binnewies","year":"2019","unstructured":"Binnewies M, et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell. 2019;177:556-571.e516. https:\/\/doi.org\/10.1016\/j.cell.2019.02.005.","journal-title":"Cell"},{"key":"2736_CR265","doi-asserted-by":"publisher","first-page":"8426","DOI":"10.7150\/thno.45286","volume":"9","author":"CB Rodell","year":"2019","unstructured":"Rodell CB, Ahmed MS, Garris CS, Pittet MJ, Weissleder R. Development of Adamantane-Conjugated TLR7\/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics. 2019;9:8426\u201336. https:\/\/doi.org\/10.7150\/thno.45286.","journal-title":"Theranostics"},{"key":"2736_CR266","doi-asserted-by":"publisher","unstructured":"Rolig AS, et al. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7\/8 agonist) improves systemic antitumor CD8(+) T cell cytotoxicity over BEMPEG+RT. J Immunother Cancer. 2022; 10. https:\/\/doi.org\/10.1136\/jitc-2021-004218","DOI":"10.1136\/jitc-2021-004218"},{"key":"2736_CR267","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1097\/mpa.0000000000001649","volume":"49","author":"HA Assi","year":"2020","unstructured":"Assi HA, Shikdar S, Alhyari L, Aljumaily R. Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer. Pancreas. 2020;49:e95\u20136. https:\/\/doi.org\/10.1097\/mpa.0000000000001649.","journal-title":"Pancreas"},{"key":"2736_CR268","doi-asserted-by":"publisher","unstructured":"Moini K. et al. Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate. Oncologist. 2025; 30. https:\/\/doi.org\/10.1093\/oncolo\/oyae267","DOI":"10.1093\/oncolo\/oyae267"},{"key":"2736_CR269","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2024.100266","volume":"8","author":"AB Buya","year":"2024","unstructured":"Buya AB, Mahlangu P, Witika BA. From lab to industrial development of lipid nanocarriers using quality by design approach. Int J Pharm X. 2024;8:100266. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100266.","journal-title":"Int J Pharm X"},{"key":"2736_CR270","doi-asserted-by":"publisher","unstructured":"Osouli-Bostanabad K. et al. Microfluidic Manufacture of Lipid-Based Nanomedicines. Pharmaceutics. 2022; 14. https:\/\/doi.org\/10.3390\/pharmaceutics14091940","DOI":"10.3390\/pharmaceutics14091940"},{"key":"2736_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119266","volume":"582","author":"C Webb","year":"2020","unstructured":"Webb C, et al. Using microfluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes. Int J Pharm. 2020;582:119266. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119266.","journal-title":"Int J Pharm"},{"key":"2736_CR272","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"key":"2736_CR273","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20200190","volume":"2","author":"X Liu","year":"2021","unstructured":"Liu X, Meng H. Consideration for the scale-up manufacture of nanotherapeutics\u2014a critical step for technology transfer. VIEW. 2021;2:20200190. https:\/\/doi.org\/10.1002\/VIW.20200190.","journal-title":"VIEW"},{"key":"2736_CR274","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303567120","volume":"120","author":"SJ Shepherd","year":"2023","unstructured":"Shepherd SJ, et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc Natl Acad Sci U S A. 2023;120:e2303567120. https:\/\/doi.org\/10.1073\/pnas.2303567120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2736_CR275","doi-asserted-by":"publisher","unstructured":"Zhu C, et al. Comparative technical and operational assessment of current and emerging bench-scale lipid nanoparticle platforms for production of mRNA vaccines. Vaccine. 2026; X 28, 100771. https:\/\/doi.org\/10.1016\/j.jvacx.2025.100771","DOI":"10.1016\/j.jvacx.2025.100771"},{"key":"2736_CR276","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17435889.2025.2587715","volume":"21","author":"N Rostami","year":"2026","unstructured":"Rostami N, et al. Advancing RNA delivery with ionizable lipid nanoparticles: the roles of microfluidics and machine learning. Nanomedicine (Lond). 2026;21:289\u2013304. https:\/\/doi.org\/10.1080\/17435889.2025.2587715.","journal-title":"Nanomedicine (Lond)"},{"key":"2736_CR277","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101299","volume":"32","author":"S Saffie-Siebert","year":"2024","unstructured":"Saffie-Siebert S, et al. Toward a large-batch manufacturing process for silicon-stabilized lipid nanoparticles: a highly customizable RNA delivery platform. Mol Ther Methods Clin Dev. 2024;32:101299. https:\/\/doi.org\/10.1016\/j.omtm.2024.101299.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2736_CR278","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102314","author":"MM Mahmud","year":"2024","unstructured":"Mahmud MM, Pandey N, Winkles JA, Woodworth GF, Kim AJ. Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials. Nano Today. 2024. https:\/\/doi.org\/10.1016\/j.nantod.2024.102314.","journal-title":"Nano Today"},{"key":"2736_CR279","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20:817\u201338. https:\/\/doi.org\/10.1038\/s41573-021-00283-5.","journal-title":"Nat Rev Drug Discov"},{"key":"2736_CR280","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","volume":"30","author":"H Muramatsu","year":"2022","unstructured":"Muramatsu H, et al. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine. Mol Ther. 2022;30:1941\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.001.","journal-title":"Mol Ther"},{"key":"2736_CR281","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jconrel.2023.03.039","volume":"357","author":"S Meulewaeter","year":"2023","unstructured":"Meulewaeter S, et al. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J Control Release. 2023;357:149\u201360. https:\/\/doi.org\/10.1016\/j.jconrel.2023.03.039.","journal-title":"J Control Release"},{"key":"2736_CR282","doi-asserted-by":"publisher","unstructured":"Rodr\u00edguez, F. et al. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules. 2022; 12. https:\/\/doi.org\/10.3390\/biom12060784","DOI":"10.3390\/biom12060784"},{"key":"2736_CR283","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1557\/s43577-021-00132-1","volume":"46","author":"I Gessner","year":"2021","unstructured":"Gessner I. Optimizing nanoparticle design and surface modification toward clinical translation. MRS Bull. 2021;46:643\u20139. https:\/\/doi.org\/10.1557\/s43577-021-00132-1.","journal-title":"MRS Bull"},{"key":"2736_CR284","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acs.molpharmaceut.3c00735","volume":"21","author":"S Wang","year":"2024","unstructured":"Wang S, et al. Unleashing the Potential: Designing Antibody-Targeted Lipid Nanoparticles for Industrial Applications with CMC Considerations and Clinical Outlook. Mol Pharm. 2024;21:4\u201317. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c00735.","journal-title":"Mol Pharm"},{"key":"2736_CR285","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jconrel.2024.07.021","volume":"373","author":"M Biscaia-Caleiras","year":"2024","unstructured":"Biscaia-Caleiras M, Fonseca NA, Louren\u00e7o AS, Moreira JN, Sim\u00f5es S. Rational formulation and industrial manufacturing of lipid-based complex injectables: landmarks and trends. J Control Release. 2024;373:617\u201339. https:\/\/doi.org\/10.1016\/j.jconrel.2024.07.021.","journal-title":"J Control Release"},{"key":"2736_CR286","doi-asserted-by":"publisher","unstructured":"Chugh, V., Vijaya Krishna, K. & Pandit, A. Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation. ACS Nano. 2021; 15: 17080\u201317123. https:\/\/doi.org\/10.1021\/acsnano.1c03800","DOI":"10.1021\/acsnano.1c03800"},{"key":"2736_CR287","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1039\/d2na00485b","volume":"4","author":"M Ramachandran","year":"2022","unstructured":"Ramachandran M, Ma Z, Lin K, De Souza C, Li Y. Transformable nanoparticles to bypass biological barriers in cancer treatment. Nanoscale Adv. 2022;4:4470\u201380. https:\/\/doi.org\/10.1039\/d2na00485b.","journal-title":"Nanoscale Adv"},{"key":"2736_CR288","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12951-022-01451-4","volume":"20","author":"RG Tuguntaev","year":"2022","unstructured":"Tuguntaev RG, et al. Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations. J Nanobiotechnology. 2022;20:236. https:\/\/doi.org\/10.1186\/s12951-022-01451-4.","journal-title":"J Nanobiotechnology"},{"key":"2736_CR289","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18:205\u201327. https:\/\/doi.org\/10.1080\/17425247.2021.1828339.","journal-title":"Expert Opin Drug Deliv"},{"key":"2736_CR290","doi-asserted-by":"publisher","first-page":"11341","DOI":"10.1021\/acsnano.1c00687","volume":"15","author":"IV Zelepukin","year":"2021","unstructured":"Zelepukin IV, et al. Long-term fate of magnetic particles in mice: a comprehensive study. ACS Nano. 2021;15:11341\u201357. https:\/\/doi.org\/10.1021\/acsnano.1c00687.","journal-title":"ACS Nano"},{"key":"2736_CR291","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1166\/jbn.2020.2928","volume":"16","author":"N Daems","year":"2020","unstructured":"Daems N, et al. In Vivo Pharmacokinetics, Biodistribution and Toxicity of Antibody-Conjugated Gold Nanoparticles in Healthy Mice. J Biomed Nanotechnol. 2020;16:985\u201396. https:\/\/doi.org\/10.1166\/jbn.2020.2928.","journal-title":"J Biomed Nanotechnol"},{"key":"2736_CR292","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.2147\/ijn.S443168","volume":"19","author":"K Jakic","year":"2024","unstructured":"Jakic K, et al. Long-term accumulation, biological effects and toxicity of BSA-coated gold nanoparticles in the mouse liver, spleen, and kidneys. Int J Nanomedicine. 2024;19:4103\u201320. https:\/\/doi.org\/10.2147\/ijn.S443168.","journal-title":"Int J Nanomedicine"},{"key":"2736_CR293","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jconrel.2020.05.027","volume":"324","author":"R Mohammadpour","year":"2020","unstructured":"Mohammadpour R, et al. One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility. J Control Release. 2020;324:471\u201381. https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.027.","journal-title":"J Control Release"},{"key":"2736_CR294","doi-asserted-by":"publisher","first-page":"15760","DOI":"10.1039\/d2nr03546d","volume":"14","author":"T L\u00e9cuyer","year":"2022","unstructured":"L\u00e9cuyer T, et al. Fate and biological impact of persistent luminescence nanoparticles after injection in mice: a one-year follow-up. Nanoscale. 2022;14:15760\u201371. https:\/\/doi.org\/10.1039\/d2nr03546d.","journal-title":"Nanoscale"},{"key":"2736_CR295","doi-asserted-by":"publisher","unstructured":"d'Avanzo, N. et al. Immunogenicity of Polyethylene Glycol Based Nanomedicines: Mechanisms, Clinical Implications and Systematic Approach. Advanced Therapeutics 3, 1900170 (2020). https:\/\/doi.org\/10.1002\/adtp.201900170","DOI":"10.1002\/adtp.201900170"},{"key":"2736_CR296","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11357-021-00495-y","volume":"44","author":"L D\u00e9zsi","year":"2022","unstructured":"D\u00e9zsi L, et al. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor. Geroscience. 2022;44:597\u2013618. https:\/\/doi.org\/10.1007\/s11357-021-00495-y.","journal-title":"Geroscience"},{"key":"2736_CR297","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603039","volume":"11","author":"NM La-Beck","year":"2020","unstructured":"La-Beck NM, Islam MR, Markiewski MM. Nanoparticle-induced complement activation: implications for cancer nanomedicine. Front Immunol. 2020;11:603039. https:\/\/doi.org\/10.3389\/fimmu.2020.603039.","journal-title":"Front Immunol"},{"key":"2736_CR298","doi-asserted-by":"publisher","unstructured":"Kyriakides TR, et al. Biocompatibility of nanomaterials and their immunological properties. Biomed Mater. 2021; 16. https:\/\/doi.org\/10.1088\/1748-605X\/abe5fa","DOI":"10.1088\/1748-605X\/abe5fa"},{"key":"2736_CR299","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3389\/fvets.2020.00447","volume":"7","author":"K Robinson","year":"2020","unstructured":"Robinson K, et al. A Pilot Study on the Safety of a Novel Antioxidant Nanoparticle Delivery System and Its Indirect Effects on Cytokine Levels in Four Dogs. Front Vet Sci. 2020;7:447. https:\/\/doi.org\/10.3389\/fvets.2020.00447.","journal-title":"Front Vet Sci"},{"key":"2736_CR300","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.003","volume":"318","author":"N Benne","year":"2020","unstructured":"Benne N, et al. Atomic force microscopy measurements of anionic liposomes reveal the effect of liposomal rigidity on antigen-specific regulatory T cell responses. J Control Release. 2020;318:246\u201355. https:\/\/doi.org\/10.1016\/j.jconrel.2019.12.003.","journal-title":"J Control Release"},{"key":"2736_CR301","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1633","volume":"12","author":"C Giannakou","year":"2020","unstructured":"Giannakou C, et al. Nonclinical regulatory immunotoxicity testing of nanomedicinal products: proposed strategy and possible pitfalls. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12:e1633. https:\/\/doi.org\/10.1002\/wnan.1633.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"2736_CR302","doi-asserted-by":"publisher","unstructured":"Soares S, Sousa J, Pais A & Vitorino C. Nanomedicine: Principles, Properties, and Regulatory Issues. 2023; https:\/\/doi.org\/10.3389\/fchem.2018.00360","DOI":"10.3389\/fchem.2018.00360"},{"key":"2736_CR303","doi-asserted-by":"publisher","unstructured":"Paradiso P, et al 2024 Regulatory Aspects of the Development of Drugs Against NASH: How the Design of a Successful Clinical Trial Could Be the Key to Regulatory Approval https:\/\/doi.org\/10.3390\/ph17030312","DOI":"10.3390\/ph17030312"},{"key":"2736_CR304","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.07.007","author":"M Germain","year":"2023","unstructured":"Germain M, et al. Delivering the power of nanomedicine to patients today. 2023. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.007.","journal-title":"Delivering the power of nanomedicine to patients today"},{"key":"2736_CR305","doi-asserted-by":"publisher","DOI":"10.3389\/ftox.2024.1393330","author":"MG Soliman","year":"2024","unstructured":"Soliman MG, et al. Protocols for isolation and characterization of nanoparticle biomolecular corona complexes. 2024. https:\/\/doi.org\/10.3389\/ftox.2024.1393330.","journal-title":"Protocols for isolation and characterization of nanoparticle biomolecular corona complexes"},{"key":"2736_CR306","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912273","author":"BY Kim","year":"2023","unstructured":"Kim BY, Rutka JT, Chan WC. Nanomedicine. 2023. https:\/\/doi.org\/10.1056\/NEJMra0912273.","journal-title":"Nanomedicine"},{"key":"2736_CR307","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612906114","author":"YS Zhang","year":"2023","unstructured":"Zhang YS, et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. 2023. https:\/\/doi.org\/10.1073\/pnas.1612906114.","journal-title":"Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors"},{"key":"2736_CR308","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0104-6","author":"A Sontheimer-Phelps","year":"2023","unstructured":"Sontheimer-Phelps A, Hassell BA, Ingber DE. Modelling cancer in microfluidic human organs-on-chips. 2023. https:\/\/doi.org\/10.1038\/s41568-018-0104-6.","journal-title":"Modelling cancer in microfluidic human organs-on-chips"},{"key":"2736_CR309","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8430","author":"A Palladini","year":"2023","unstructured":"Palladini A, Chiaramonte M. Adaptive trial designs in diagnostic accuracy research. 2023. https:\/\/doi.org\/10.1002\/sim.8430.","journal-title":"Adaptive trial designs in diagnostic accuracy research"},{"key":"2736_CR310","doi-asserted-by":"publisher","unstructured":"Bauer P, Koenig F, Brannath W & Posch M. Selection and bias--two hostile brothers. 2023; https:\/\/doi.org\/10.1002\/sim.3716","DOI":"10.1002\/sim.3716"},{"key":"2736_CR311","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000438226.10353.1c","author":"SP Hey","year":"2023","unstructured":"Hey SP, Kimmelman J. The questionable use of unequal allocation in confirmatory trials. 2023. https:\/\/doi.org\/10.1212\/01.wnl.0000438226.10353.1c.","journal-title":"The questionable use of unequal allocation in confirmatory trials"},{"key":"2736_CR312","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.08.023","author":"V Sainz","year":"2023","unstructured":"Sainz V, et al. Regulatory aspects on nanomedicines. 2023. https:\/\/doi.org\/10.1016\/j.bbrc.2015.08.023.","journal-title":"Regulatory aspects on nanomedicines"},{"key":"2736_CR313","doi-asserted-by":"publisher","DOI":"10.1021\/ar200019c","author":"T Lammers","year":"2023","unstructured":"Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. 2023. https:\/\/doi.org\/10.1021\/ar200019c.","journal-title":"Theranostic nanomedicine"},{"key":"2736_CR314","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2012.05.013","author":"ML Etheridge","year":"2023","unstructured":"Etheridge ML, et al. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. 2023. https:\/\/doi.org\/10.1016\/j.nano.2012.05.013.","journal-title":"The big picture on nanomedicine: the state of investigational and approved nanomedicine products"},{"key":"2736_CR315","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2018.09.005","author":"S Hua","year":"2023","unstructured":"Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization. 2023. https:\/\/doi.org\/10.1016\/j.nantod.2018.09.005.","journal-title":"Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: Pathways for translational development and commercialization"},{"key":"2736_CR316","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-017-0175-0","author":"S Tran","year":"2023","unstructured":"Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. 2023. https:\/\/doi.org\/10.1186\/s40169-017-0175-0.","journal-title":"Cancer nanomedicine: a review of recent success in drug delivery"},{"key":"2736_CR317","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2014.06.011","author":"SM Moghimi","year":"2023","unstructured":"Moghimi SM, Farhangrazi ZS. Just so stories: the random acts of anti-cancer nanomedicine performance. 2023. https:\/\/doi.org\/10.1016\/j.nano.2014.06.011.","journal-title":"Just so stories: the random acts of anti-cancer nanomedicine performance"},{"key":"2736_CR318","doi-asserted-by":"publisher","unstructured":"Hu Z, Ott PA & Wu C J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. 2023; https:\/\/doi.org\/10.1038\/nri.2017.131","DOI":"10.1038\/nri.2017.131"},{"key":"2736_CR319","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","author":"RS Riley","year":"2023","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. 2023. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Delivery technologies for cancer immunotherapy"},{"key":"2736_CR320","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120452","author":"GH Nam","year":"2023","unstructured":"Nam GH, et al. Tumor targeting peptide-conjugated bio-inspired bimetallic hydroxide nanohybrids for enhanced chemodynamic therapy and tumor ablation. 2023. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120452.","journal-title":"Tumor targeting peptide-conjugated bio-inspired bimetallic hydroxide nanohybrids for enhanced chemodynamic therapy and tumor ablation"},{"key":"2736_CR321","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13193","author":"Q Chen","year":"2023","unstructured":"Chen Q, et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. 2023. https:\/\/doi.org\/10.1038\/ncomms13193.","journal-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy"},{"key":"2736_CR322","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201802228","author":"Q Chen","year":"2023","unstructured":"Chen Q, et al. Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy. 2023. https:\/\/doi.org\/10.1002\/adma.201802228.","journal-title":"Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy"},{"key":"2736_CR323","doi-asserted-by":"publisher","DOI":"10.3791\/61048","author":"Y Li","year":"2023","unstructured":"Li Y, Ayala-Orozco C, Rauta PR, Krishnan S. Fabricating biodegradable nanoparticles that contain a fluorescent dye and drugs. 2023. https:\/\/doi.org\/10.3791\/61048.","journal-title":"Fabricating biodegradable nanoparticles that contain a fluorescent dye and drugs"},{"key":"2736_CR324","doi-asserted-by":"publisher","unstructured":"Min Y, Caster JM, Eblan MJ & Wang AZ. Clinical Translation of Nanomedicine. 2023; https:\/\/doi.org\/10.1021\/acs.chemrev.5b00116","DOI":"10.1021\/acs.chemrev.5b00116"},{"key":"2736_CR325","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.139","author":"RK Jain","year":"2023","unstructured":"Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. 2023. https:\/\/doi.org\/10.1038\/nrclinonc.2010.139.","journal-title":"Delivering nanomedicine to solid tumors"},{"key":"2736_CR326","doi-asserted-by":"publisher","unstructured":"Wicki A, Witzigmann D, Balasubramanian V. & Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. 2023. https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.030","DOI":"10.1016\/j.jconrel.2014.12.030"},{"key":"2736_CR327","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.04.025","author":"JI Hare","year":"2023","unstructured":"Hare JI, et al. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. 2023. https:\/\/doi.org\/10.1016\/j.addr.2016.04.025.","journal-title":"Challenges and strategies in anti-cancer nanomedicine development: An industry perspective"},{"key":"2736_CR328","doi-asserted-by":"publisher","unstructured":"Liu J, Lu G & Li Z. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. 2024; 21, 751\u2013766. https:\/\/doi.org\/10.1038\/s41423-024-01226-x","DOI":"10.1038\/s41423-024-01226-x"},{"key":"2736_CR329","doi-asserted-by":"publisher","unstructured":"Chowdhury SM. et al. Blood\u2013Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Challenges. 2024. 16: 3300. https:\/\/doi.org\/10.3390\/cancers16193300","DOI":"10.3390\/cancers16193300"},{"key":"2736_CR330","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1007\/s13346-021-01008-2","volume":"11","author":"SJ Bagley","year":"2021","unstructured":"Bagley SJ, Nabavizadeh SA, Mays JJ. Overcoming delivery barriers in immunotherapy for glioblastoma. 2021;11:2332\u201347. https:\/\/doi.org\/10.1007\/s13346-021-01008-2.","journal-title":"Overcoming delivery barriers in immunotherapy for glioblastoma"},{"key":"2736_CR331","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1021\/acsnano.1c08120","volume":"16","author":"Q Meng","year":"2022","unstructured":"Meng Q, Gong N, Ma H. Smart Nanomedicine to Enable Crossing Blood-Brain Barrier Delivery into Brain Diseases by Biomimicry and Bioorthogonal Conjugation Strategies. 2022;16:104\u201316. https:\/\/doi.org\/10.1021\/acsnano.1c08120.","journal-title":"Smart Nanomedicine to Enable Crossing Blood-Brain Barrier Delivery into Brain Diseases by Biomimicry and Bioorthogonal Conjugation Strategies"},{"key":"2736_CR332","doi-asserted-by":"publisher","unstructured":"Zardini A, Li J & Yu Y. Device-assisted strategies for drug delivery across the blood\u2013brain barrier in glioblastoma. 2024; 5: 6. https:\/\/doi.org\/10.1038\/s43246-024-00721-y","DOI":"10.1038\/s43246-024-00721-y"},{"key":"2736_CR333","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-024-04564-y","volume":"166","author":"CE Fadul","year":"2024","unstructured":"Fadul CE, et al. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide. J Neurooncol. 2024;166:321\u201330. https:\/\/doi.org\/10.1007\/s11060-024-04564-y.","journal-title":"J Neurooncol"},{"key":"2736_CR334","doi-asserted-by":"publisher","unstructured":"Zhu Y, Chen S & Liu W. Recent Advances in Indocyanine Green-Based Probes for NIR-II Imaging and Imaging-Guided Therapy. 2024; 7: 0583. https:\/\/doi.org\/10.34133\/research.0583","DOI":"10.34133\/research.0583"},{"key":"2736_CR335","doi-asserted-by":"publisher","unstructured":"Lee JS, Kim H & Lee JY. Indocyanine Green-Loaded PLGA Nanoparticles Conjugated with Hyaluronic Acid Improve Targeting and Phototherapeutic Effect in CD44-Positive Breast Cancer. 2021; 62: 1042\u20131050. https:\/\/doi.org\/10.3349\/ymj.2021.62.11.1042","DOI":"10.3349\/ymj.2021.62.11.1042"},{"key":"2736_CR336","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s42247-020-00142-9","volume":"4","author":"P Singh","year":"2021","unstructured":"Singh P, et al. Gold nanomaterials in the management of lung cancer. 2021;4:111\u201324. https:\/\/doi.org\/10.1007\/s42247-020-00142-9.","journal-title":"Gold nanomaterials in the management of lung cancer"},{"key":"2736_CR337","doi-asserted-by":"publisher","unstructured":"Zhang, H. et al. Bridging preclinical and clinical fluorescence-guided surgery with advanced cancer vision goggles. Npj Imaging. 2026; 4. https:\/\/doi.org\/10.1038\/s44303-026-00170-x","DOI":"10.1038\/s44303-026-00170-x"},{"key":"2736_CR338","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.3390\/cancers16244141","volume":"16","author":"X Ma","year":"2024","unstructured":"Ma X, Chi C, Zhu X. Potential Probes for Targeted Intraoperative Fluorescence Imaging of Gastric Cancer. 2024;16:4141. https:\/\/doi.org\/10.3390\/cancers16244141.","journal-title":"Potential Probes for Targeted Intraoperative Fluorescence Imaging of Gastric Cancer"},{"key":"2736_CR339","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111173","volume":"27","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li J, Wang S. Advances in nanoparticle-based radiotherapy for cancer treatment. 2024;27:111173. https:\/\/doi.org\/10.1016\/j.isci.2024.111173.","journal-title":"Advances in nanoparticle-based radiotherapy for cancer treatment"},{"key":"2736_CR340","doi-asserted-by":"publisher","unstructured":"Bonvalot S, Rutkowski PL & Thariat J. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a phase 2\u20133, randomised, multicentre trial. 2019; 20: 1148\u20131159. https:\/\/doi.org\/10.1016\/S1470-2045(19)30326-2","DOI":"10.1016\/S1470-2045(19)30326-2"},{"key":"2736_CR341","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.rpor.2019.10.007","volume":"25","author":"A Akbari","year":"2020","unstructured":"Akbari A, Amanpour S, Muhammadnejad S. Protection effect of cerium oxide nanoparticles against radiation-induced acute lung injuries in rats. 2020;25:41\u20136. https:\/\/doi.org\/10.1016\/j.rpor.2019.10.007.","journal-title":"Protection effect of cerium oxide nanoparticles against radiation-induced acute lung injuries in rats"},{"key":"2736_CR342","doi-asserted-by":"publisher","unstructured":"Bonvalot S, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial. Lancet. Oncol. 2019; 20: 1148\u20131159. https:\/\/doi.org\/10.1016\/s1470-2045(19)30326-2","DOI":"10.1016\/s1470-2045(19)30326-2"},{"key":"2736_CR343","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41598-023-27729-7","volume":"13","author":"MR Kibria","year":"2023","unstructured":"Kibria MR, et al. Predicting efficacy of drug-carrier nanoparticle designs for cancer treatment: a machine learning-based solution. Sci Rep. 2023;13:547. https:\/\/doi.org\/10.1038\/s41598-023-27729-7.","journal-title":"Sci Rep"},{"key":"2736_CR344","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mdr2.70043","volume":"2","author":"RC Sahu","year":"2026","unstructured":"Sahu RC, Arora S, Kumar D, Agrawal AK. Machine learning for predictive modeling in nanomedicine-based cancer drug delivery. Med Res. 2026;2:130\u201356. https:\/\/doi.org\/10.1002\/mdr2.70043.","journal-title":"Med Res"},{"key":"2736_CR345","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202407793","volume":"36","author":"XJ Gao","year":"2024","unstructured":"Gao XJ, et al. Toward the integration of machine learning and molecular modeling for designing drug delivery nanocarriers. Adv Mater. 2024;36:e2407793. https:\/\/doi.org\/10.1002\/adma.202407793.","journal-title":"Adv Mater"},{"key":"2736_CR346","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-026-01640-8","author":"LJ Su","year":"2026","unstructured":"Su LJ, et al. Artificial intelligence-guided design of LNPs for in vivo targeted mRNA delivery via analysis of the spatial conformation of ionizable lipids. Nat Biomed Eng. 2026. https:\/\/doi.org\/10.1038\/s41551-026-01640-8.","journal-title":"Nat Biomed Eng"},{"key":"2736_CR347","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.7150\/thno.102653","volume":"15","author":"J Gu","year":"2025","unstructured":"Gu J, et al. Molecular simulation-aided self-adjuvanting nanoamplifier for cancer photoimmunotherapy. Theranostics. 2025;15:2451\u201369. https:\/\/doi.org\/10.7150\/thno.102653.","journal-title":"Theranostics"},{"key":"2736_CR348","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1158\/1538-7445.AM2025-3761","volume":"85","author":"E Lewoczko","year":"2025","unstructured":"Lewoczko E, et al. Abstract 3761: AI-GPT-driven design of novel lipid nanoparticles for targeted and safe mRNA-based cancer immunotherapy. Cancer Res. 2025;85:3761\u20133761. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-3761.","journal-title":"Cancer Res"},{"key":"2736_CR349","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202519567","volume":"36","author":"Y Shan","year":"2026","unstructured":"Shan Y, et al. Deep learning-driven co-assembly of naturally sourced compound nanoparticles for potentiated cancer immunotherapy. Adv Funct Mater. 2026;36:e19567. https:\/\/doi.org\/10.1002\/adfm.202519567.","journal-title":"Adv Funct Mater"},{"key":"2736_CR350","doi-asserted-by":"publisher","unstructured":"Bhujel R, & et al. Artificial Intelligence-Driven Strategies for Targeted Delivery and Enhanced Stability of RNA-Based Lipid Nanoparticle Cancer Vaccines. Pharmaceutics. 2025; 17: 992. https:\/\/doi.org\/10.3390\/pharmaceutics17080992","DOI":"10.3390\/pharmaceutics17080992"},{"key":"2736_CR351","doi-asserted-by":"publisher","unstructured":"Imani, S. & et al. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front Cell Infect Microbiol. 2025; 14: 1501010. https:\/\/doi.org\/10.3389\/fcimb.2024.1501010","DOI":"10.3389\/fcimb.2024.1501010"},{"key":"2736_CR352","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2025.1528826","volume":"7","author":"A Alalmaie","year":"2025","unstructured":"Alalmaie A, et al. Integrating computational insights in gold nanoparticle-mediated drug delivery: enhancing efficacy and precision. Front Med Technol. 2025;7:1528826. https:\/\/doi.org\/10.3389\/fmedt.2025.1528826.","journal-title":"Front Med Technol"},{"key":"2736_CR353","doi-asserted-by":"publisher","unstructured":"Kong X, et al. Nanoparticle-based immunotherapeutic strategies to overcome cancer drug resistance: From biological barriers to artificial intelligence-driven design. Drug Resistance Updates. 2026 86: 101392. https:\/\/doi.org\/10.1016\/j.drup.2026.101392","DOI":"10.1016\/j.drup.2026.101392"},{"key":"2736_CR354","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/17435889.2026.2628239","volume":"21","author":"VF Merino","year":"2026","unstructured":"Merino VF, Saini N, Fernandes R. Advancing prussian blue nanoparticle-mediated photothermal therapy through machine learning and multiomics integration. Nanomedicine (Lond). 2026;21:823\u201338. https:\/\/doi.org\/10.1080\/17435889.2026.2628239.","journal-title":"Nanomedicine (Lond)"},{"key":"2736_CR355","doi-asserted-by":"publisher","unstructured":"Han Y, Kim DH & Pack SP. Nanomaterials in Drug Delivery: Leveraging Artificial Intelligence and Big Data for Predictive Design. Int J Mol Sci. 2025; 26. https:\/\/doi.org\/10.3390\/ijms262211121","DOI":"10.3390\/ijms262211121"},{"key":"2736_CR356","doi-asserted-by":"publisher","first-page":"13185","DOI":"10.1021\/acssuschemeng.4c03592","volume":"12","author":"A Mottafegh","year":"2024","unstructured":"Mottafegh A, Yang J, Na G-S, Kim D-P. Self-Driving Synthesis of Protein Nanoparticles by Active Transfer-Learning-Assisted Autonomous Flow Platform. ACS Sustain Chem Eng. 2024;12:13185\u201396. https:\/\/doi.org\/10.1021\/acssuschemeng.4c03592.","journal-title":"ACS Sustain Chem Eng"},{"key":"2736_CR357","doi-asserted-by":"publisher","DOI":"10.3390\/pr11061717","volume":"11","author":"P Phalak","year":"2023","unstructured":"Phalak P, et al. Digital twin implementation for manufacturing of adjuvants. Processes. 2023;11:1717.","journal-title":"Processes"},{"key":"2736_CR358","doi-asserted-by":"publisher","unstructured":"Chandler M. & et al. Artificial Immune Cell, AI-cell, a New Tool to Predict Interferon Production by Peripheral Blood Monocytes in Response to Nucleic Acid Nanoparticles. Small. 2022; 18: e2204941. https:\/\/doi.org\/10.1002\/smll.202204941","DOI":"10.1002\/smll.202204941"},{"key":"2736_CR359","doi-asserted-by":"publisher","unstructured":"Li Y & et al. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano. 2024; 18: 28649\u201328658. https:\/\/doi.org\/10.1021\/acsnano.4c05087","DOI":"10.1021\/acsnano.4c05087"},{"key":"2736_CR360","doi-asserted-by":"publisher","unstructured":"Liric Rajlic, I. & et al. Translational kinetic-pharmacodynamics of mRNA-6231, an investigational mRNA therapeutic encoding mutein interleukin-2. CPT Pharmacometrics Syst Pharmacol. 2024; 13: 1067\u20131078. https:\/\/doi.org\/10.1002\/psp4.13142","DOI":"10.1002\/psp4.13142"},{"key":"2736_CR361","doi-asserted-by":"publisher","unstructured":"Pu, X. & et al. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study. EClinicalMedicine. 2024;67:102403. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102403.","DOI":"10.1016\/j.eclinm.2023.102403"},{"key":"2736_CR362","doi-asserted-by":"publisher","unstructured":"Bhatt Deepak L. & Mehta C. Adaptive Designs for Clinical Trials. New Engl J Med. 2016;375(1):65\u201374. https:\/\/doi.org\/10.1056\/NEJMra1510061.","DOI":"10.1056\/NEJMra1510061"},{"key":"2736_CR363","doi-asserted-by":"publisher","unstructured":"Chou WC. & et al. Machine Learning and Artificial Intelligence in Nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025; 17: e70027. https:\/\/doi.org\/10.1002\/wnan.70027","DOI":"10.1002\/wnan.70027"},{"key":"2736_CR364","doi-asserted-by":"publisher","unstructured":"Schoppe O. & et al. Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning. Nat Biotechnol. 2025; https:\/\/doi.org\/10.1038\/s41587-024-02528-1","DOI":"10.1038\/s41587-024-02528-1"},{"key":"2736_CR365","doi-asserted-by":"publisher","unstructured":"Wang D, Prueksaritanont T & Huang S. CRISPR-Cas9-mediated gene editing in human tripronuclear zygotes. 2015; 6: 363\u2013372. https:\/\/doi.org\/10.1007\/s13238-015-0153-5","DOI":"10.1007\/s13238-015-0153-5"},{"key":"2736_CR366","doi-asserted-by":"publisher","unstructured":"Liu Q, Zhao K & Wang C. Multistage Delivery Nanoparticle Facilitates Efficient CRISPR\/dCas9 Activation and Tumor Selective Translation in a Stage-Specific Manner. 2019; 19: 8609\u20138619. https:\/\/doi.org\/10.1021\/acs.nanolett.9b03429","DOI":"10.1021\/acs.nanolett.9b03429"},{"key":"2736_CR367","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1038\/s41467-018-06603-5","volume":"9","author":"S Deng","year":"2018","unstructured":"Deng S, Li X, Liu S. Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation. 2018;9:4333. https:\/\/doi.org\/10.1038\/s41467-018-06603-5.","journal-title":"Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation"},{"key":"2736_CR368","doi-asserted-by":"publisher","unstructured":"Charlesworth CT, Deshpande PS & Dever DP. Identification of preexisting adaptive immunity to Cas9 proteins in humans. 2019; 25: 249\u2013254. https:\/\/doi.org\/10.1038\/s41591-018-0326-x","DOI":"10.1038\/s41591-018-0326-x"},{"key":"2736_CR369","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11095-017-2288-4","volume":"35","author":"SK Alsaiari","year":"2018","unstructured":"Alsaiari SK, Patil S, Alyami M. Endosomal Escape and Transfection Efficiency of PEGylated Cationic Liposome-DNA Complexes Prepared with Optimized Lipid Compositions. 2018;35:58. https:\/\/doi.org\/10.1007\/s11095-017-2288-4.","journal-title":"Endosomal Escape and Transfection Efficiency of PEGylated Cationic Liposome-DNA Complexes Prepared with Optimized Lipid Compositions"},{"key":"2736_CR370","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","volume":"36","author":"Z Glass","year":"2018","unstructured":"Glass Z, Lee M, Li Y, Xu Q. Engineering the Delivery System for CRISPR-Based Genome Editing. 2018;36:173\u201385. https:\/\/doi.org\/10.1016\/j.tibtech.2017.11.006.","journal-title":"Engineering the Delivery System for CRISPR-Based Genome Editing"},{"key":"2736_CR371","doi-asserted-by":"publisher","unstructured":"Gopalakrishnan V, Spencer CN & Nezi L. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. 2018; 359: 97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","DOI":"10.1126\/science.aan4236"},{"key":"2736_CR372","doi-asserted-by":"publisher","unstructured":"Tanoue T, Morita S & Plichta DR. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. 2019; 565: 600\u2013605. https:\/\/doi.org\/10.1038\/s41586-019-0878-0","DOI":"10.1038\/s41586-019-0878-0"},{"key":"2736_CR373","doi-asserted-by":"publisher","unstructured":"Smith PM, Howitt MR & Panikov N. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. 2013; 341: 569\u2013573. https:\/\/doi.org\/10.1126\/science.1241165","DOI":"10.1126\/science.1241165"},{"key":"2736_CR374","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2019.07.028","volume":"157","author":"S Bashiardes","year":"2019","unstructured":"Bashiardes S, Thaiss CA, Elinav E. It\u2019s in the Weeds: Herbicide Linked to Human Liver Disease. 2019;157:618\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2019.07.028.","journal-title":"It's in the Weeds: Herbicide Linked to Human Liver Disease"},{"key":"2736_CR375","doi-asserted-by":"publisher","unstructured":"Routy B, Le Chatelier E & Derosa L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. 2018; 359: 91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","DOI":"10.1126\/science.aan3706"},{"key":"2736_CR376","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359:1366\u201370. https:\/\/doi.org\/10.1126\/science.aar6918.","journal-title":"Science"},{"key":"2736_CR377","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. 2021;371:602\u20139. https:\/\/doi.org\/10.1126\/science.abb5920.","journal-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients"},{"key":"2736_CR378","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","volume":"143","author":"A Vrieze","year":"2012","unstructured":"Vrieze A, Van Nood E, Holleman F. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. 2012;143:913-916.e917. https:\/\/doi.org\/10.1053\/j.gastro.2012.06.031.","journal-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome"},{"key":"2736_CR379","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2018.08.041","volume":"174","author":"N Zmora","year":"2018","unstructured":"Zmora N, Zilberman-Schapira G, Suez J. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. 2018;174:1388-1405.e1321. https:\/\/doi.org\/10.1016\/j.cell.2018.08.041.","journal-title":"Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features"},{"key":"2736_CR380","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-16-2929","volume":"77","author":"S Thomas","year":"2017","unstructured":"Thomas S, Izard J, Walsh E. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. 2017;77:1783\u2013812. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2929.","journal-title":"The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists"},{"key":"2736_CR381","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120826","volume":"274","author":"SJ Shepherd","year":"2021","unstructured":"Shepherd SJ, Issadore D, Mitchell MJ. Microfluidic formulation of nanoparticles for biomedical applications. Biomaterials. 2021;274:120826. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.120826.","journal-title":"Biomaterials"},{"key":"2736_CR382","doi-asserted-by":"publisher","DOI":"10.1039\/d3ra01234a","author":"S Garg","year":"2023","unstructured":"Garg S, Garg A, Enaganti S, Yadav AK. Microfluidics Based Synthesis of Nanoparticles for Biomedical Applications. 2023. https:\/\/doi.org\/10.1039\/d3ra01234a.","journal-title":"Microfluidics Based Synthesis of Nanoparticles for Biomedical Applications"},{"key":"2736_CR383","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release"},{"key":"2736_CR384","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2217\/nnm-2018-0364","volume":"14","author":"B Halamoda-Kenzaoui","year":"2019","unstructured":"Halamoda-Kenzaoui B, et al. Anticipation of regulatory needs for nanotechnology-enabled health products: the anticipated road from research to market. Nanomedicine (Lond). 2019;14:881\u201398. https:\/\/doi.org\/10.2217\/nnm-2018-0364.","journal-title":"Nanomedicine (Lond)"},{"key":"2736_CR385","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"2736_CR386","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.addr.2009.06.003","volume":"61","author":"R Gaspar","year":"2009","unstructured":"Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev. 2009;61:1220\u201331. https:\/\/doi.org\/10.1016\/j.addr.2009.06.003.","journal-title":"Adv Drug Deliv Rev"},{"key":"2736_CR387","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1016\/j.vaccine.2019.05.029","volume":"37","author":"Z Kis","year":"2019","unstructured":"Kis Z, Papathanasiou M, Calvo-Serrano R, Kontoravdi C, Shah N. A model-based quantification of the impact of new manufacturing technologies on developing country vaccine supply chain performance: a Kenyan case study. Vaccine. 2019;37:3527\u201339. https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.029.","journal-title":"Vaccine"},{"key":"2736_CR388","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1016\/j.vaccine.2020.06.079","volume":"38","author":"Z Kis","year":"2020","unstructured":"Kis Z, Kontoravdi C, Dey AK, Shattock R, Shah N. Rapid development and deployment of high-volume vaccines for epidemic response. Vaccine. 2020;38:5849\u201356. https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.079.","journal-title":"Vaccine"},{"key":"2736_CR389","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-60327-198-1_1","volume":"697","author":"SE McNeil","year":"2011","unstructured":"McNeil SE. Characterization of nanoparticles intended for drug delivery. Methods Mol Biol. 2011;697:3\u20138. https:\/\/doi.org\/10.1007\/978-1-60327-198-1_1.","journal-title":"Methods Mol Biol"},{"key":"2736_CR390","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","volume":"103","author":"K Maier-Hauff","year":"2011","unstructured":"Maier-Hauff K, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103:317\u201324. https:\/\/doi.org\/10.1007\/s11060-010-0389-0.","journal-title":"J Neurooncol"},{"key":"2736_CR391","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","volume":"14","author":"R van der Meel","year":"2019","unstructured":"van der Meel R, et al. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14:1007\u201317. https:\/\/doi.org\/10.1038\/s41565-019-0567-y.","journal-title":"Nat Nanotechnol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02736-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:31:46Z","timestamp":1785519106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02736-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":391,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2736"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02736-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"185"}}